Longevity Health Holdings, Inc 8-K/A, filed Aug 15, 2023
Longevity Health Holdings, Inc. (XAGE)
About this 8-K/A
Longevity Health Holdings, Inc filed this 8-K/A on August 15, 2023, reporting on events of July 14, 2023.
Items reported
- Item 2.01: Completed an acquisition or sale of assets
- Item 5.02: Director or officer change, or executive pay
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
(Amendment No. 1)
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
(
(Registrant’s telephone number, including area code)
Alpha Healthcare Acquisition Corp. III2
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencements communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbols |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
| 1 | Name as of the original filing of the Current Report on Form 8-K amended hereby. The address is unchanged since such filing. |
| 2 | Prior to the original filing of the Current Report on Form 8-K amended hereby. |
Explanatory Note
This Amendment No. 1 on Form 8-K (“Amendment No. 1”) amends Item 9.01 of the Current Report on Form 8-K filed by Carmell Corporation (the “Company”) on July 20, 2023 (the “Original Report”) in which the Company reported, among other events, the consummation of the Business Combination (as defined in the Original Report). As of the date of the Original Report, the Company’s name was Carmell Therapeutics Corporation.
This Amendment No. 1 hereby amends the subsections of Item 2.01 identified below and Item 9.01 in the Original Report to include (i) the unaudited financial statements of Legacy Carmell (as defined in the Original Report) as of and for the six months ended June 30, 2023 and 2022, (ii) the Management’s Discussion and Analysis of Financial Condition and Results of Operations of Legacy Carmell for the six months ended June 30, 2023 and (iii) the unaudited pro forma condensed combined financial information as of and for the six months ended June 30, 2023. This Amendment No. 1 also hereby amends the subsections of Item 5.02 identified below to update certain of the information therein.
The text of the Original Report is hereby incorporated by reference. This Amendment No. 1 solely amends the subsections of Item 2.01 and 5.02 identified below, and Item 2.01 and 5.02 of the Original Report otherwise remains unchanged, and Item 9.01 of the Original Report. This Amendment No. 1 does not amend any other item of the Original Report or purport to provide an update or a discussion of any developments at the Company or its subsidiaries subsequent to the filing date of the Original Report. Capitalized terms not otherwise defined herein shall have the respective meanings ascribed to them in the Original Report.
| Item 2.01. | Completion of Acquisition or Disposition of Assets. |
Financial Information
Selected Historical Financial Information
Reference is made to the disclosure in Item 9.01 of this Current Report, which is incorporated herein by reference.
Unaudited Financial Statements
Reference is made to the disclosure in Item 9.01 of this Current Report, which is incorporated herein by reference.
Unaudited Pro Forma Condensed Combined Financial Information
The unaudited pro forma condensed combined financial information of Carmell as of and for the six months ended June 30, 2023 and for the year ended December 31, 2022 is set forth in Exhibit 99.3 hereto and is incorporated herein by reference. The unaudited pro forma condensed combined financial information is derived from, and should be read in conjunction with, the historical financial statements and related notes of Legacy Carmell and ALPA for the applicable periods included elsewhere in this Current Report, and in ALPA’s Amended Annual Report on Form 10-K, filed with the SEC on May 16, 2023 (the “ALPA 10-K/A”). The unaudited pro forma condensed combined financial information should also be read in conjunction with the section of this Current Report entitled “Management’s Discussion and Analysis of Financial Conditions and Results of Operations” and the section of the ALPA 10-K/A entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”
Management’s Discussion and Analysis of Financial Condition and Results of Operations
Management’s discussion and analysis of the financial condition and results of operation of Legacy Carmell for the years ended December 31, 2022 and 2021 is included in the Proxy Statement/prospectus in the section entitled “Information about Carmell — Management’s Discussion and Analysis of Financial Condition and Results of Operations of Carmell Therapeutics Corporation”, beginning on page 220 of the Proxy Statement/prospectus, which is incorporated herein by reference. Management’s discussion and analysis of the financial condition and results of operation of Legacy Carmell for the six months ended June 30, 2023 and 2022 is set forth on Exhibit 99.2 hereto and are incorporated herein by reference.
| Item 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
The Company wishes to amend and restate the information included under the subheading “Executive Officers” in the Original Report as described below.
Executive Officers
Upon consummation of the Business Combination, the following individuals were appointed to serve as executive officers of Carmell:
| Name |
Age | Position(s) | ||||
| Rajiv Shukla |
48 | Executive Chairman | ||||
| Randolph W. Hubbell |
60 | Chief Executive Officer, President and Director | ||||
| Bryan Cassaday |
55 | Interim Chief Financial Officer | ||||
| James Hart, M.D. |
71 | Chief Medical Officer | ||||
| Donna Godward |
68 | Chief Quality Officer | ||||
| Janet Vargo, Ph.D. |
65 | Vice President Clinical Services | ||||
Bryan Cassaday has been the Interim Chief Financial Officer of Carmell since June 2023. Mr. Cassaday has over 30 years of experience serving in strategic financial leadership positions across multiple industries ranging in size from mid-size private-equity portfolio companies to large, publicly traded corporations. Prior to Carmell Corporation, Mr. Cassaday was the Controller for Nevakar, Inc., a commercial-stage biopharmaceutical with an extensive portfolio of products in the ophthalmic and critical care injectables areas. In this role, Mr. Cassaday managed the accounting, finance, financial reporting, and planning functions. Prior to Nevakar, Mr. Cassaday was the Chief Financial Officer of Atalian Global Services from 2019 to 2020, Controller and Acting Chief Financial Officer of EMCOR Facilities Services from 2015 to 2019, and Controller of SeeChange Health from 2013 to 2015. From 1993 to 2013, Mr. Cassaday held accounting and finance leadership roles at Nationwide Financial, Prevail InfoWorks, Delaware Investments, and Delphi Financial Group. Mr. Cassaday began his career in Ernst & Young’s assurance group, where he was a senior auditor from 1990 to 1993.
Mr. Cassaday received his B.S. in Accounting from Drexel University and is a Certified Public Accountant and Chartered Global Management Accountant.
Reference is made to the section of the Proxy Statement/prospectus entitled “Management of the Combined Company,” beginning on page 260 of the Proxy Statement/prospectus, which is incorporated herein by reference.
| Item 9.01. | Financial Statements and Exhibits. |
| (a) | Financial statements of businesses acquired. |
Reference is made to the audited consolidated financial statements of Legacy Carmell as of and for the years ended December 31, 2022 and 2021, which are set forth in the Proxy Statement/prospectus beginning on page F-70 and are incorporated herein by reference.
Reference is made to the unaudited financial statements of Legacy Carmell as of and for the six months ended June 30, 2023 and 2022, which are included as Exhibit 99.1 hereto and are incorporated herein by reference.
Management’s Discussion and Analysis of Financial Condition and Results of Operations of Legacy Carmell for the six months ended June 30, 2023 is attached hereto as Exhibit 99.2 and incorporated herein by reference.
| (b) | Pro forma financial information. |
Reference is made to the unaudited pro forma condensed combined balance sheet as of June 30, 2023 and the unaudited pro forma condensed combined statements of operations for the year ended December 31, 2022 and the six months ended June 30, 2023, which are included as Exhibit 99.3 hereto and are incorporated herein by reference.
| (d) | Exhibits |
| Exhibit Number |
Description | |
| 99.1 | Unaudited financial statements of Legacy Carmell as of and for the six months ended June 30, 2023. | |
| 99.2 | Management’s Discussion and Analysis of Financial Condition and Results of Operations of Legacy Carmell for the six months ended June 30, 2023. | |
| 99.3 | Unaudited pro forma condensed combined financial information of Carmell Corporation for the year ended December 31, 2022 and as of and for the six months ended June 30, 2023. | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: August 14, 2023
| CARMELL CORPORATION | ||
| By: | /s/ Rajiv Shukla | |
| Name: | Rajiv Shukla | |
| Title: | Executive Chairman | |
Exhibit 99.1
CARMELL THERAPEUTICS CORPORATION
CONDENSED FINANCIAL STATEMENTS
F-1
CARMELL THERAPEUTICS CORPORATION
| June 30, | December 31, | |||||||
| 2023 | 2022 | |||||||
| (Unaudited) | ||||||||
| ASSETS |
||||||||
| Current Assets: |
||||||||
| Cash |
$ | 15,920 | $ | 128,149 | ||||
| Prepaid expenses |
5,466 | 55,069 | ||||||
| Deferred offering cost |
1,317,369 | 394,147 | ||||||
| Other current assets |
— | 28,175 | ||||||
|
|
|
|
|
|||||
| Total Current Assets |
1,338,755 | 605,540 | ||||||
| Property and equipment, net of accumulated depreciation of $578,234 and $530,116, respectively |
237,326 | 254,974 | ||||||
| Operating lease right of use asset |
787,710 | 859,331 | ||||||
| Intangible assets, net of accumulated amortization of $44,301 and $42,044, respectively |
26,445 | 28,702 | ||||||
|
|
|
|
|
|||||
| Total Assets |
$ | 2,390,236 | $ | 1,748,547 | ||||
|
|
|
|
|
|||||
| LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ DEFICIT |
||||||||
| Current Liabilities: |
||||||||
| Accounts payable |
$ | 3,661,474 | $ | 2,138,732 | ||||
| Accrued expenses and other liabilities |
1,613,237 | 944,573 | ||||||
| Accrued interest |
1,008,755 | 477,720 | ||||||
| Advance from related party |
25,000 | — | ||||||
| Promissory notes, net of debt discount of $40,281 |
708,219 | — | ||||||
| Promissory notes-related parties, net of debt discount of $6,481 |
68,519 | — | ||||||
| Convertible notes payable, net of debt discount of $0 as of June 30, 2023 and December 31, 2022 |
2,777,778 | 2,777,778 | ||||||
| Derivative liabilities |
4,697,138 | 826,980 | ||||||
| Lease liability |
134,769 | 129,502 | ||||||
|
|
|
|
|
|||||
| Total Current Liabilities |
14,694,889 | 7,295,285 | ||||||
| Long-term Liabilities: |
||||||||
| Lease liability, net of current portion |
759,001 | 827,728 | ||||||
|
|
|
|
|
|||||
| Total Liabilities |
15,453,890 | 8,123,013 | ||||||
|
|
|
|
|
|||||
| Commitments and Contingencies (see Note 8) |
||||||||
| Mezzanine Equity |
||||||||
| Series C-1 preferred stock, 41,000,000 shares authorized as of June 30, 2023 and December 31, 2022; 5,090,693 shares issued and outstanding as of June 30, 2023 and December 31, 2022 |
809,667 | 772,028 | ||||||
| Series C-2 preferred stock, 75,500,000 shares authorized as of June 30, 2023 and December 31, 2022; 73,560,390 shares issued and outstanding as of June 30, 2023 and December 31, 2022 |
16,341,426 | 15,904,275 | ||||||
| Series B preferred stock, 34,622,470 shares authorized as of June 30, 2023 and December 31, 2022; 33,801,226 shares issued and outstanding as of June 30, 2023 and December 31, 2022 |
7,025,434 | 7,025,434 | ||||||
| Series A preferred stock, 19,968,051 shares authorized as of June 30, 2023 and December 31, 2022; 19,968,051 shares issued and outstanding as of June 30, 2023 and December 31, 2022 |
7,866,191 | 7,714,336 | ||||||
| Stockholders’ Deficit: |
||||||||
| Common stock, $.001 par value; 240,000,000 shares authorized at June 30, 2023 and December 31, 2022; 14,766,766 shares issued and outstanding as of June 30, 2023 and 14,531,511 at December 31, 2022 |
14,767 | 14,532 | ||||||
| Additional paid-in capital |
5,025,464 | 4,577,220 | ||||||
| Accumulated deficit |
(50,146,603 | ) | (42,382,291 | ) | ||||
|
|
|
|
|
|||||
| Total Stockholders’ Deficit |
(45,106,372 | ) | (37,790,539 | ) | ||||
|
|
|
|
|
|||||
| Total Liabilities, Mezzanine Equity and Stockholders’ Deficit |
$ | 2,390,236 | $ | 1,748,547 | ||||
|
|
|
|
|
|||||
The accompanying notes are an integral part of these condensed financial statements.
F-2
CARMELL THERAPEUTICS CORPORATION
CONDENSED STATEMENTS OF OPERATIONS
(Unaudited)
| For the Six Months Ended June 30, | ||||||||
| 2023 | 2022 | |||||||
| Operating expenses: |
||||||||
| Research and development |
$ | 1,563,982 | $ | 983,667 | ||||
| General and administrative |
1,147,898 | 837,030 | ||||||
| Depreciation and amortization of intangible assets |
50,375 | 47,019 | ||||||
|
|
|
|
|
|||||
| Total operating expenses |
2,762,255 | 1,867,716 | ||||||
|
|
|
|
|
|||||
| Loss from operations |
(2,762,255 | ) | (1,867,716 | ) | ||||
|
|
|
|
|
|||||
| Other income (expense): |
||||||||
| Other income |
34,080 | 10,874 | ||||||
| Change in fair value of derivative liabilities |
(3,870,158 | ) | 3,917,615 | |||||
| Interest expense |
(531,034 | ) | (491,764 | ) | ||||
| Amortization of debt discount |
(8,300 | ) | (1,437,821 | ) | ||||
|
|
|
|
|
|||||
| Total other income (expense) |
(4,375,412 | ) | 1,998,904 | |||||
|
|
|
|
|
|||||
| (Loss) income before provision for income taxes |
(7,137,667 | ) | 131,188 | |||||
| Provision for income taxes |
— | — | ||||||
|
|
|
|
|
|||||
| Net (loss) income |
(7,137,667 | ) | 131,188 | |||||
| Dividends on Series A, Series C-1, and C-2 preferred stock |
(626,645 | ) | (153,962 | ) | ||||
|
|
|
|
|
|||||
| Net loss attributable to common stockholders |
$ | (7,764,312 | ) | $ | (22,774 | ) | ||
|
|
|
|
|
|||||
| Net loss per common share - basic and diluted |
$ | (0.42 | ) | $ | (0.00 | ) | ||
|
|
|
|
|
|||||
| Weighted average of common shares outstanding - basic and diluted |
18,307,002 | 37,730,698 | ||||||
|
|
|
|
|
|||||
The accompanying notes are an integral part of these condensed financial statements.
F-3
CARMELL THERAPEUTICS CORPORATION
CONDENSED STATEMENT OF STOCKHOLDERS’ DEFICIT
For the Six Months Ended June 30, 2023 and 2022
(Unaudited)
| Common Stock | Treasury Stock | Additional Paid-in |
Accumulated | |||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Capital | Deficit | Total | ||||||||||||||||||||||
| Balance at January 1, 2022 |
36,918,882 | $ | 36,919 | $ | 3,160,491 | $ | (32,774,456 | ) | $ | (29,577,046 | ) | |||||||||||||||||
| Accrued Series A preferred stock dividend |
— | — | — | (153,962 | ) | (153,962 | ) | |||||||||||||||||||||
| Issuance of common stock for service |
203,666 | 204 | 26,273 | 26,477 | ||||||||||||||||||||||||
| Warrants issued in connection with notes |
— | — | 409,483 | — | 409,483 | |||||||||||||||||||||||
| Repurchase of common stock |
(7,825,387 | ) | (7,825 | ) | 7,825,387 | 783 | 7,042 | — | — | |||||||||||||||||||
| Cancellation of common stock |
— | — | (7,825,387 | ) | (783 | ) | — | — | (783 | ) | ||||||||||||||||||
| Stock-based compensation expense |
— | — | 342,866 | — | 342,866 | |||||||||||||||||||||||
| Net income |
— | — | — | — | — | 131,188 | 131,188 | |||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
| Balance at June 30, 2022 |
29,297,161 | $ | 29,298 | — | $ | — | $ | 3,946,155 | $ | (32,797,230 | ) | $ | (28,821,777 | ) | ||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
| Balance at January 1, 2023 |
14,531,511 | $ | 14,532 | — | — | $ | 4,577,220 | $ | (42,382,291 | ) | $ | (37,790,539 | ) | |||||||||||||||
| Accrued Series A preferred stock dividend |
— | — | — | — | — | (151,855 | ) | (151,855 | ) | |||||||||||||||||||
| Accrued Series C-1 preferred stock dividend |
— | — | — | — | — | (37,639 | ) | (37,639 | ) | |||||||||||||||||||
| Accrued Series C-2 preferred stock dividend |
— | — | — | — | — | (437,151 | ) | (437,151 | ) | |||||||||||||||||||
| Exercise of common stock options |
235,255 | 235 | — | — | 25,643 | — | 25,878 | |||||||||||||||||||||
| Warrants issued in connection with notes |
— | — | — | — | 55,062 | — | 55,062 | |||||||||||||||||||||
| Stock-based compensation expense |
— | — | — | — | 367,539 | — | 367,539 | |||||||||||||||||||||
| Net loss |
— | — | — | — | — | (7,137,667 | ) | (7,137,667 | ) | |||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
| Balance at June 30, 2023 |
14,766,766 | $ | 14,767 | — | $ | — | $ | 5,025,464 | $ | (50,146,603 | ) | $ | (45,106,372 | ) | ||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
The accompanying notes are an integral part of these condensed financial statements.
F-4
CARMELL THERAPEUTICS CORPORATION
CONDENSED STATEMENT OF CASH FLOWS
(Unaudited)
| For the Six Months Ended June 30 | ||||||||
| 2023 | 2022 | |||||||
| Cash flows from operating activities: |
||||||||
| Net (loss) income |
$ | (7,137,667 | ) | $ | 131,188 | |||
| Adjustments to reconcile net (loss) income to net cash used in operating activities: |
||||||||
| Depreciation and amortization of intangible assets |
50,375 | 47,019 | ||||||
| Amortization of debt discount |
8,300 | 1,437,821 | ||||||
| Amortization of ROU assets |
71,621 | 76,521 | ||||||
| Change in fair value of derivative liabilities |
3,870,158 | (3,917,615 | ) | |||||
| Stock-based compensation |
367,539 | 369,343 | ||||||
| Changes in operating assets and liabilities: |
||||||||
| Prepaid expenses |
49,603 | (35,443 | ) | |||||
| Other current assets |
28,175 | — | ||||||
| Accounts payable |
599,520 | (677,785 | ) | |||||
| Accrued expenses and other liabilities |
668,664 | 7,192 | ||||||
| Lease liability |
(63,460 | ) | (63,859 | ) | ||||
| Accrued interest-related parties |
— | 35,704 | ||||||
| Accrued interest - non-related parties |
531,035 | 362,328 | ||||||
|
|
|
|
|
|||||
| Net cash used in operating activities |
(956,137 | ) | (2,227,586 | ) | ||||
|
|
|
|
|
|||||
| Cash flows from investing activities: |
||||||||
| Purchase of property and equipment |
(30,470 | ) | (3,579 | ) | ||||
|
|
|
|
|
|||||
| Net cash used in investing activities |
(30,470 | ) | (3,579 | ) | ||||
|
|
|
|
|
|||||
| Cash flows from financing activities: |
||||||||
| Proceeds from convertible notes |
— | 2,687,514 | ||||||
| Proceeds from promissory notes |
748,500 | — | ||||||
| Proceeds from promissory notes-related parties |
75,000 | — | ||||||
| Proceeds from exercise of stock options |
25,878 | — | ||||||
| Advance from related party |
25,000 | — | ||||||
| Repurchase of common stock |
— | (783 | ) | |||||
| Payment of debt financing fee |
— | (382,222 | ) | |||||
|
|
|
|
|
|||||
| Net cash provided by financing activities |
874,378 | 2,304,509 | ||||||
|
|
|
|
|
|||||
| Net (decrease) increase in cash |
(112,229 | ) | 73,344 | |||||
| Cash - beginning of the period |
128,149 | 12,362 | ||||||
|
|
|
|
|
|||||
| Cash - end of the period |
$ | 15,920 | $ | 85,706 | ||||
|
|
|
|
|
|||||
| Supplemental cash flow information: |
||||||||
| Interest paid |
$ | — | $ | 92,593 | ||||
|
|
|
|
|
|||||
| Income tax paid |
$ | — | $ | — | ||||
|
|
|
|
|
|||||
| Non-cash financing activity: |
||||||||
| Warrants issued in connection with promissory notes |
$ | 46,800 | $ | 409,483 | ||||
|
|
|
|
|
|||||
| Warrants issued in connection with promissory notes-related parties |
$ | 8,262 | $ | — | ||||
|
|
|
|
|
|||||
| Accrued Series A preferred stock dividends |
$ | 151,855 | $ | 153,962 | ||||
|
|
|
|
|
|||||
| Accrued Series C-1 preferred stock dividends |
$ | 37,639 | $ | — | ||||
| Accrued Series C-2 preferred stock dividends |
$ | 437,151 | $ | — | ||||
|
|
|
|
|
|||||
| Initial recognition of derivative liabilities |
$ | — | $ | 1,267,860 | ||||
|
|
|
|
|
|||||
| Unpaid deferred offering costs |
$ | 923,222 | $ | 1,229,941 | ||||
|
|
|
|
|
|||||
The accompanying notes are an integral part of these condensed financial statements.
F-5
CARMELL THERAPEUTICS CORPORATION
(Unaudited)
NOTE 1 — NATURE OF THE ORGANIZATION AND BUSINESS
Carmell Therapeutics Corporation (“Carmell” or the “Company”) was incorporated in the State of Delaware in November 2008. With operations in Pittsburgh, Pennsylvania, its mission is to expand and commercialize technology developed jointly at Carnegie Mellon University and Allegheny General Hospital. The proprietary technology enables the manufacture of biologically active plastics from blood plasma for treating injuries to bone and soft tissue and to promote hair growth and collagen production. These plastics are sterile, off-the-shelf, easy to handle, shape, and suture, have controlled degradation rates, and contain known bioactivity levels.
The Company is focused on products designed to enhance and accelerate healing and produce better clinical outcomes in orthopedic trauma, dental bone graft substitutes, advanced wound care, and aesthetic medicine. The Company is currently conducting research and development activities to operationalize certain patented technology that the Company owns and licenses. The Company is initiating and assessing regulatory efforts and pathways in Europe and the United States.
Risks and Uncertainties
Management continues to evaluate the impact of the COVID-19 pandemic and the Russia-Ukraine war on the economy and the capital markets. It has concluded that while it is reasonably possible that such events could adversely affect the Company’s financial position, the specific impacts are not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of these uncertainties.
The current challenging economic climate may lead to adverse changes in cash flows, working capital levels, and/or debt balances, which may also directly impact the Company’s future operating results and financial position. The ultimate duration and magnitude of the impact and the efficacy of government interventions on the economy and the financial effect on the Company is not known at this time. The extent of such impact will depend on future developments, which are highly uncertain and not in the Company’s control.
NOTE 2 — BUSINESS COMBINATION AGREEMENT
On January 4, 2023, Alpha Healthcare Acquisition Corp. III, a Delaware corporation (“Alpha” and, after the Business Combination, “New Carmell”), entered into a business combination agreement (the “Business Combination Agreement”) by and among Alpha, Candy Merger Sub, Inc., a Delaware corporation (“Merger Sub”), and the Company. The Business Combination Agreement provides, among other things, that on the terms and subject to the conditions set forth therein, Merger Sub will merge with and into the Company, with the Company surviving as a wholly-owned subsidiary of Alpha (the “Business Combination”).
Under the Business Combination Agreement, Alpha will acquire all of the outstanding equity interests of the Company in exchange for shares of Class A common stock of Alpha, par value $0.0001 per share (the “Class A Common Stock”), based on the Company’s implied equity value of $150,000,000, to be paid to the Company’s stockholders at the effective time of the Business Combination.
Under the Business Combination Agreement, at or prior to the effective time of the Business Combination, each option and warrant exercisable for the Company’s equity that is outstanding immediately prior to the effective time of the Business Combination shall be assumed by Alpha and continue in full force and effect on the same terms and conditions as are currently applicable to such options and warrants, subject to adjustments to exercise price and number of shares of Class A Common Stock issued upon exercise.
On July 11, 2023, at a special meeting of stockholders, the stockholders of Alpha approved the merger and other transactions contemplated by the Business Combination Agreement. The Business Combination closed on July 14, 2023, and the shares of New Carmell commenced trading on the Nasdaq Capital Market on July 17, 2023.
F-6
NOTE 3 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation
The unaudited financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) for interim financial information. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. These financial statements should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2022. The accompanying unaudited condensed financial statements include all adjustments of a normal recurring nature and necessary for the fair presentation of the results for the interim periods presented. Results for interim periods are not necessarily indicative of results to be expected for the full year.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity-based transactions, and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period.
Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation, or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future events. Accordingly, actual results could differ significantly from the estimates included in these financial statements.
Cash
The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company has no cash equivalents as of June 30, 2023 and December 31, 2022.
Property and Equipment
Property and equipment are stated at cost less accumulated depreciation. Maintenance and repair charges are expensed as incurred. The assets are depreciated using the straight-line method using the following useful lives:
Lab equipment – 5-7 years
Leasehold improvements - The lesser of 10 years or the remaining life of the lease
Furniture and fixtures – 7 years
Intangible Assets
Intangible assets consist entirely of patent costs. The Company capitalizes legal costs directly associated with the submission of Company patent applications. Gross patent costs of $70,746 as of June 30, 2023 and December 31, 2022 are amortized on a straight-line basis over the patent term and are stated net of accumulated amortization of $44,301 and $42,044, respectively. No asset impairment was recognized during the six months ended June 30, 2023 and 2022. Amortization expense for the six months ended June 30, 2023 and 2022, was $2,257 and $2,239, respectively. Costs billed to the Company as reimbursement for third parties’ patent submissions are considered as license fees and expensed as incurred.
Offering Costs Associated with a Public Offering
The Company complies with the requirements of FASB ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (“SAB”) Topic 5A - “Expenses of Offering.” ASC 340-10-S99-1 states that specific incremental costs directly attributable to a proposed or actual offering of equity securities incurred prior to the effective date of the offering
F-7
may be deferred and charged against the gross proceeds of the offering when the offering occurs. The costs of an aborted offering may not be deferred and charged against the proceeds of a subsequent offering. In October 2022, the Company aborted an S-1 IPO Offering and started pursuing an acquisition by a SPAC. In October 2022, the Company wrote off the costs capitalized relating to the S-1 IPO. As of June 30, 2023 and December 31, 2022, the Company had capitalized deferred offering costs relating to the SPAC acquisition of $1,317,369 and $394,147, respectively.
Impairment of Long-Lived Assets
The Company reviews long-lived assets for impairment whenever events or circumstances indicate that the carrying value of such assets may not be fully recoverable. Impairment is present when the sum of estimated undiscounted future cash flow expected to result from use of the assets is less than the carrying value. If impairment is present, the carrying value of the impaired asset is reduced to its fair value. Fair value is determined based on discounted cash flow or appraised values, depending on the nature of the assets. No impairment losses were recognized for long-lived assets for the six months ended June 30, 2023 and 2022.
Income Taxes
Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.
ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of June 30, 2023 and December 31, 2022. The Company is currently not aware of any issues under review that could result in significant payments, accruals, or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities for tax years ended 2019 to 2022.
Fair Value Measurements and Fair Value of Financial Instruments
Our financial instruments consist primarily of accounts payable, accrued expenses, and short-term debt. The carrying value of accounts payable and accrued expenses approximates fair value because of the short-term maturity of such instruments.
We have categorized our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy in accordance with GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3).
Assets and liabilities recorded in the balance sheet at fair value as of June 30, 2023 and December 31, 2022 are categorized based on a hierarchy of inputs as follows:
| Carrying | Fair Value Measurement Using | |||||||||||||||||||
| Value | Level 1 | Level 2 | Level 3 | Total | ||||||||||||||||
| Derivative liability at June 30, 2023 |
$ | 4,697,138 | $ | — | $ | — | $ | 4,697,138 | $ | 4,697,138 | ||||||||||
| Derivative liability at December 31, 2022 |
$ | 826,980 | $ | — | $ | — | $ | 826,980 | $ | 826,980 | ||||||||||
F-8
| Fair Value Measurements Using Significant Unobservable Inputs (Level 3) |
||||||||
| June 30, 2023 | December 31, 2022 | |||||||
| Balance, beginning of year |
$ | 826,980 | $ | 3,846,319 | ||||
| Initial recognition of derivative liability |
— | 1,321,860 | ||||||
| Settled in Series C-2 preferred stock |
— | (3,081,912 | ) | |||||
| Change in fair value of derivative liability |
3,870,158 | (1,259,287 | ) | |||||
|
|
|
|
|
|||||
| Balance, end of period |
$ | 4,697,138 | $ | 826,980 | ||||
|
|
|
|
|
|||||
Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.
Level 2 - Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data.
Level 3 - Inputs are unobservable inputs that reflect the reporting entity’s assumptions on the assumptions the market participants would use to price the asset or liability based on the best available information.
The fair value of the embedded derivatives in the convertible notes as of June 30, 2023 and December 31, 2022 was valued using a Monte-Carlo model and was based upon the following management assumptions:
| June 30, 2023 | December 31, 2022 | |||||||
| Stock price |
$ | 0.62 | $ | 0.16 | ||||
| Expected term (years) |
0.25 | 0.04 | ||||||
| Volatility |
69.7 | % | 55.1 | % | ||||
| Risk-free interest rate |
5.06 | % | 4.38 | % | ||||
| Probability of Qualified Financing or IPO |
100.00 | % | 50.00 | % | ||||
| Probability of a Change in Control Event |
0.00 | % | 10.00 | % | ||||
The December 31, 2022 stock price was derived from a 409A valuation. The stock price at June 30, 2023 was based on the conversion ratio of Carmell shares into Alpha shares in connection with the Business Combination and the market price of the shares of Alpha, the acquiring public company, as of June 30, 2023. At June 30, 2023, there was a 100% probability of the business combination occurring. The volatility was determined from the historical volatility of comparable public companies over the expected terms. The term was based on the maturity date of the note. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued. The probability of a Qualified Financing or IPO and a Change of Control Event were based on the Company’s assessment of such an event occurring.
Research and Development Costs
The Company is currently conducting research and development activities to operationalize certain patented technology that the Company owns and licenses. The Company expenses costs related to these activities in the period incurred.
Net Loss Per Share
Net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per share is computed like basic earnings per share, except the weighted average number of common shares outstanding is increased to include additional shares from the assumed exercise of share options if dilutive. The dilutive effect, if any, of convertible instruments or warrants is calculated using the treasury stock method. There are no outstanding dilutive instruments as the outstanding convertible instruments, and warrants would be anti-dilutive if converted or exercised as of June 30, 2023 and 2022.
F-9
The following table summarizes the securities that were excluded from the diluted per share calculation because the effect of including these potential shares was anti-dilutive due to the Company’s net loss position even though the exercise price could be less than the average market price of the common shares:
| Six Months Ended June 30, | ||||||||
| 2023 | 2022 | |||||||
| Series A Preferred Stock (if converted) |
19,968,051 | 19,968,051 | ||||||
| Series B Preferred Stock (if converted) |
33,801,226 | 32,917,690 | ||||||
| Series C-1 Preferred Stock (if converted) |
5,090,693 | — | ||||||
| Series C-2 Preferred Stock (if converted) |
73,560,390 | — | ||||||
| Stock Options |
37,135,725 | 35,690,469 | ||||||
| Common Stock Warrants (penny warrants excluded) |
1,677,086 | 1,758,975 | ||||||
| Preferred Stock Warrants |
3,758,186 | 1,704,759 | ||||||
| Convertible Notes |
34,423,019 | 17,142,832 | ||||||
|
|
|
|
|
|||||
| Total |
209,414,376 | 109,182,776 | ||||||
|
|
|
|
|
|||||
Stock-Based Compensation
The Company applies the provisions of ASC 718, Compensation-Stock Compensation (“ASC 718”), which requires the measurement and recognition of compensation expense for all stock-based awards made to employees, including employee stock options, in the statements of operations.
For stock options issued to employees and members of the Board of Directors (the “Board) for their services, the Company estimates each option’s grant date fair value using the Black-Scholes option pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates, and expected dividend yields of the common stock. For awards subject to service-based vesting conditions, including those with a graded vesting schedule, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock options on a straight-line basis over the requisite service period, generally the vesting term. Forfeitures are recorded as incurred instead of estimated at the time of grant and revised.
Under Accounting Standards Update (“ASU”) 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Payment Accounting, the Company accounts for stock options issued to non-employees for their services in accordance with ASC 718. The Company uses valuation methods and assumptions to value the stock options that are in line with the process for valuing employee stock options noted above.
Leases
The Company adopted ASC Topic 842, Leases, as amended, on January 1, 2020. We elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed the Company not to separate non-lease components from lease components and instead to account for each separate lease component and the non-lease components associated with that lease component as a single lease.
The Company’s leases consist of leaseholds on office space. The Company determines if an arrangement contains a lease at inception as defined by ASC 842. To meet the definition of a lease under ASC 842, the contractual arrangement must convey to us the right to control the use of an identifiable asset for a period of time in exchange for consideration. Right of Use (“ROU”) assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term.
F-10
Recent Accounting Pronouncements
On June 30, 2022, the FASB issued ASU 2022-03, which (1) clarifies the guidance in ASC 820 on the fair value measurement of an equity security that is subject to a contractual sale restriction and (2) requires specific disclosures related to such equity security. The amendments in ASU 2022-03 are consistent with the principles of fair value measurement under which an entity is required to consider characteristics of an asset or liability if other market participants would also consider those characteristics when pricing the asset or liability. Specifically, the ASU clarifies that an entity should apply these fair value measurement principles to equity securities subject to contractual sale restrictions. The Company does not believe that, if adopted, ASU 2022-03 would have a material effect on the Company’s financial statements.
NOTE 4 — GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS
As of June 30, 2023 and December 31, 2022, the Company had cash of $15,920 and $128,149, respectively, and an accumulated deficit of $50,146,603 and $42,382,291, respectively. The Company’s liquidity needs up to June 30, 2023 have been satisfied through debt and equity financing.
For the six months ended June 30, 2023 and 2022, the Company had a loss from operations of $2,762,255 and $1,867,716, respectively, and negative cash flows from operations of $956,137 and $2,227,586, respectively.
Due to its current liabilities and other potential liabilities, the cash available to the Company may not be sufficient to allow the Company to operate for at least 12 months from the date these financial statements are available for issuance. The Company may need to raise additional capital through equity or debt issuances. If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, curtailing operations and reducing overhead expenses. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all.
On July 19, 2022, the Company defaulted on the January 2022 convertible notes. Pursuant to the terms of the note, upon an event of default, there would be a 25% increase to the outstanding principal in addition to the interest rate increase from 10% to 18%.
These conditions raise substantial doubt about the Company’s ability to continue as a going concern. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.
NOTE 5 — PROPERTY AND EQUIPMENT
Property and equipment consist of the following:
| June 30, 2023 |
December 31, 2022 |
|||||||
| Lab equipment |
$ | 696,648 | $ | 666,178 | ||||
| Leasehold improvements |
115,333 | 115,333 | ||||||
| Furniture and fixtures |
3,579 | 3,579 | ||||||
|
|
|
|
|
|||||
| 815,560 | 785,090 | |||||||
| Less: accumulated depreciation |
(578,234 | ) | (530,116 | ) | ||||
|
|
|
|
|
|||||
| Property and equipment, net |
$ | 237,326 | $ | 254,974 | ||||
|
|
|
|
|
|||||
Depreciation expense was $48,118 and $44,780 for the six months ended June 30, 2023 and 2022, respectively.
NOTE 6 — ACCRUED EXPENSES AND OTHER LIABILITIES
Accrued expenses and other liabilities consist of the following amounts:
| June 30, 2023 |
December 31, 2022 |
|||||||
| Accrued compensation |
$ | 1,509,222 | $ | 916,934 | ||||
| Other |
104,015 | 27,639 | ||||||
|
|
|
|
|
|||||
| Accrued expenses and other liabilities |
$ | 1,613,237 | $ | 944,573 | ||||
|
|
|
|
|
|||||
F-11
Accrued compensation is a non-interest bearing liability for employee payroll outstanding on June 30, 2023 and December 31, 2022. This includes compensation earned during the years 2019 to 2023.
NOTE 7 — CONVERTIBLE NOTES AND PROMISSORY NOTES
Series 1 Convertible Notes
These convertible notes have been issued between July 9, 2018 (the first initial closing) and September 13, 2019. All of the notes were issued with the same maturity date, July 8, 2021 (three years from the initial closing). The notes bear interest at 8%, have no monthly payments, and are due in full with a balloon payment on the maturity date. The notes contain an embedded conversion feature whereby the outstanding principal and accrued and unpaid interest are automatically convertible upon a Qualified Financing, which is defined as new series of preferred stock whose rights, preferences, or privileges are senior to the existing Series B preferred stock, with gross proceeds of at least $5,000,000, into the same shares (preferred stock) as issued in the offering. The conversion price is the lesser of (i) the price per share for the new preferred stock purchased in the Qualified Financing, multiplied by eighty percent (80%) and (ii) the price per share equal to the quotient of $20,000,000, divided by, the number of outstanding shares of the Company’s common stock and preferred stock, plus any outstanding warrants for capital stock of Company, outstanding stock options to purchase common stock and any shares of common stock reserved for issuance under the Company’s stock incentive plan. The outstanding principal and all accrued and unpaid interest are also convertible into the same series of stock issued at the holders’ option if there is a non-qualified financing, which is the sale of a new series of preferred stock that does not qualify as a Qualified Financing. The conversion price is the same as the automatic conversion under a Qualified Financing. This conversion feature meets the definition of a derivative and was valued using the Monte Carlo model, with the fair value of the derivative being recorded as a derivative liability (see Note 2) and debt discount at the time of issuance. The maturity date of the notes was extended on July 8, 2021 to September 9, 2021, on September 9, 2021 to July 9, 2022, and again on January 6, 2022 to July 9, 2023. Management determined that these extensions were debt modifications. On September 23, 2022, a Qualified Financing occurred, at which point all outstanding principal and accrued and unpaid interest were converted to Preferred Series C-2 Shares. The principal and interest converted was $6,109,560 and $1,829,865, respectively, which converted into 35,686,682 and 10,688,464 shares, respectively, at a ratio of $0.1712 per share. The fair value of the shares issued was $15,595,283. The fair value of the derivative upon conversion was $1,938,481. The Company incurred interest expense of $242,373 and amortization of debt discount expense of $0 during the six months ended June 30, 2022. Certain of these notes are with related parties (see Note 11).
Series 2 Convertible Notes
These convertible notes have been issued between September 25, 2019 (the first initial closing) and December 31, 2021. All of the notes were issued with the same maturity date, September 24, 2022 (three years from the initial closing). The notes bear interest at 8%, have no monthly payments, and are due in full with a balloon payment on the maturity date. The notes contain an embedded conversion feature whereby the outstanding principal and accrued and unpaid interest are automatically convertible upon a Qualified Financing, which is defined as new series of preferred stock whose rights, preferences, or privileges are senior to the existing Series B preferred stock, with gross proceeds of at least $5,000,000, into the same shares (preferred stock) as issued in the offering. The conversion price is the lesser of (i) the price per share for the new preferred stock purchased in the Qualified Financing, multiplied by eighty percent (80%) and (ii) the price per share equal to the quotient of $20,000,000, divided by, the number of outstanding shares of the Company’s common stock and preferred stock, plus any outstanding warrants for capital stock of Company, outstanding stock options to purchase common stock and any shares of common stock reserved for issuance under the Company’s stock incentive plan. The outstanding principal and all accrued and unpaid interest are also convertible into the same series of stock issued at the holders’ option if there is a non-qualified financing, which is the sale of a new series of preferred stock that does not qualify as a Qualified Financing. The conversion price is the same as the automatic conversion under a Qualified Financing. This conversion feature meets the definition of a derivative and was valued using the Monte Carlo model, with the fair value of the derivative being recorded as a derivative liability
F-12
(see Note 2) and debt discount at the time of issuance. On September 23, 2022, a Qualified Financing occurred, at which point all outstanding principal and accrued and unpaid interest was converted into Preferred Series C-2 Shares. The principal and interest converted was $3,965,455 and $629,920, respectively, which converted into 23,162,704 and 3,679,439 shares, respectively, at a ratio of $0.1712 per share. The fair value of the shares issued was $5,717,377. The fair value of the derivative upon conversion was $1,122,002. The Company incurred interest expense of $149,303 and amortization of debt discount expense of $684,890 during the six months ended June 30, 2022.
Other Convertible Note
The Company issued a convertible note to an economic development fund for $50,000 on June 24, 2020. The note is non-interest bearing, has no monthly payments, and is due in full with a balloon payment on June 23, 2025. The note contains an embedded conversion feature whereby the note holder can convert the shares at a discount in the event of a Qualified Financing or a change in control event. This conversion feature meets the definition of a derivative and was valued using the Monte Carlo model, with the fair value of the derivative being recorded as a derivative liability (see Note 2) and debt discount at the time of issuance. On September 23, 2022, a Qualified Financing occurred, at which point all outstanding principal was converted to Preferred Series C-2 Shares. The principal converted was $50,000, which converted into 343,157 shares at a ratio of $0.1457 per share. The fair value of the shares issued was $73,092. The fair value of the derivative upon conversion was $23,092. The debt discount at the time of conversion was $47,872, which was written off as a loss on debt extinguishment. During the six months ended June 30, 2022, there was $706 of amortization of debt discount.
January 2022 Convertible Notes
On January 19, 2022, the Company issued two senior secured convertible notes (the “Convertible Notes”) of $1,111,111 each to two investors (“Holders”), due on January 19, 2023. The notes bear interest at 10% (18% upon default). The Company is required to make monthly interest payments for the interest incurred and required monthly principal payments of $158,730 beginning on July 19, 2022. The notes are collateralized by all assets (including current and future intellectual property) of the Company. These two notes were issued with a 10% discount and were subject to an 8% commission due to the underwriter. These fees were recorded as debt discount. In addition, the Holders received from the Company a warrant to subscribe for and purchase up to 1,885,796 shares (3,771,592 shares in total) of the Company’s common stock. Each warrant is exercisable at a price of $0.01 per warrant share, vests immediately upon closing (the “Initial Exercise Date”) and has a term of 5 years. The fair value of the warrants was $409,483, which was recorded as debt discount. The senior secured convertible notes are convertible at the option of the Holders into shares of common stock at a fixed conversion price equal to the lesser of $0.22 per share and a 25% discount to the price of the common stock in a Qualified Offering (as adjusted, the “Conversion Price”). In the event units consisting of common stock and warrants are issued in a Qualified Offering, the senior secured convertible notes shall be convertible into common stock and warrants. If, at any time while the Convertible Note is outstanding, the Company sells or grants any option to purchase or sells or grants any right to reprice, or otherwise disposes of or issues (or announces any sale, grant or any option to purchase or other disposition), any common stock or common stock equivalents entitling any Person to acquire shares of common stock at an effective price per share that is lower than the then Conversion Price (such lower price, the “Base Conversion Price”), then the Conversion Price shall be reduced to equal the Base Conversion Price. Such adjustment shall be made whenever such common stock or common stock equivalents are issued. Multiple events during the year ended December 31, 2022 triggered the down-round feature of the base conversion price. As of June 30, 2023 and December 31, 2022, the Base Conversion Price was $0.11.
The conversion feature within these convertible notes meets the requirements to be treated as a derivative. Accordingly, the Company estimated the fair value of the convertible notes derivative using the Monte Carlo Method as of the date of issuance. The fair value of the derivative was determined to be $1,110,459 at the time of issuance and was recorded as a liability with an offsetting amount recorded as a debt discount. The derivative is revalued at the end of each reporting period, and any change in fair value is recorded as a gain or loss in the statement of operations.
F-13
Proceeds from the sales of the Convertible Notes with stock purchase warrants were allocated to the two elements based on the relative fair value of the notes without the warrants and the warrants themselves at the time of issuance. The total amount allocated to warrants was $409,483 and accounted for as paid-in capital. The discount amount was calculated by determining the aggregate fair value of the warrants using the Black-Scholes Option Pricing Model.
On July 19, 2022, the Company defaulted on the debt. Under the terms of the note, upon an event of default, there would be a 25% increase to the outstanding principal, in addition to the interest rate increasing from 10% to 18%. Upon the event of default, the unamortized debt discount of $958,899 was accelerated and expensed. The outstanding principal balance of the notes was $2,777,778 at June 30, 2023 and December 31, 2022. During the six months ended June 30, 2023, interest expense for these notes was $531,034, consisting of $250,000 of interest and $281,034 of late fees and penalties. During the six months ended June 30, 2022, interest expense for these notes was $100,088. Amortization of debt discount expense for these notes was $752,225 for the six months ended June 30, 2022.
On November 2, 2022, the Company received a letter (“Notice of Acceleration”) from one of the Holders, notifying an Event of Default. As of the date of issuance, the Company is currently in default on these notes.
An Agreement Subsequent to the Notice of Acceleration
The Company entered into an agreement with one of the Holders (“Puritan”) in connection with the Notice of Acceleration on December 19, 2022. Pursuant to the agreement, Alpha and the Company each represented and warranted to Puritan that (i) it intends to enter into a business combination agreement (“the Business Combination Agreement”) among Alpha, the Company and Merger Sub ( as defined in the Business Combination Agreement, (ii) there will be no conditions to closing relating to Alpha or its affiliates delivering a certain amount of cash to the Company at closing of the Business Combination (the “Closing”), (iii) the only conditions to Closing of the merger are as set forth in Sections 6.1 through Section 6.3 of the Business Combination Agreement, (iv) upon entering into such Business Combination Agreement, such parties shall have a commitment letter from a third party to provide capital in an amount sufficient to the surviving company to the Business Combination to, among other things, repay all amounts due and owing at such time to Puritan at the Closing, (v) the equity valuation ascribed to the Company in the Business Combination Agreement is $150 million, and (vi) such Business Combination Agreement shall not place any restrictions on Puritan’s ability to transfer any of its securities, including, without limitation, the shares underlying the Puritan Warrant. The Company agreed it would not pay any other debtholder on account of interest or principal during the forbearance period hereunder.
Based on the representations and warranties, and agreements above and in consideration of the Company’s agreement to pay Puritan at the Closing; (i) the outstanding principal amount, plus accrued interest, late fees and all other amounts then owed as specified in the 2022 Note, including without limitation, Sections 8(b) and 2(c) of the 2022 Note (the “2022 Note Payoff Amount”) - as of the date of such agreement, the parties acknowledged that $1,610,413 was due ($1,627,749 as of December 31, 2022) and owed under the 2022 Note and (ii) 25,000 freely tradable shares of Alpha (not subject to lock-up or any other restrictions on transfer) at a price of $10.00 per common share (i.e., the price per share of common stock to the equity holders of the Company in the Business Combination), Puritan withdrew and rescinded the Notice of Acceleration, and such Notice of Acceleration was deemed null and void and had no further force or effect. Puritan further agreed that, based on the representations and warranties, and agreements contained in such agreement, it shall not issue any further notices of acceleration or default notices under the 2022 Note or other 2022 Note Documentation, seek repayment of any amounts due under the 2022 Note, or seek to exercise any other remedies contained in the 2022 Note or other 2022 Note Documentation in regard to non-payment of the 2022 Note, from the Effective Date until the Outside Date (as defined below).
Notwithstanding the foregoing, the Notice of Acceleration will be automatically reinstated with an effective date of November 2, 2022, upon the earliest to occur of (i) June 30, 2023, if the Closing has not occurred prior to such date, (ii) the Company and/or Alpha provide notice to Puritan that they have mutually agreed not to pursue a business combination transaction, or (iii) Alpha or the Company publicly announce that the Business Combination Agreement has been terminated by either party (the first occurrence of (i), (ii) or (iii), the “Outside Date”)
F-14
2023 Promissory Notes
During the six months ended June 30, 2023, the Company received $823,500 from 25 zero coupon Promissory Notes (the “Notes”). Three of the notes were from related parties and represented $75,000 of the borrowings. The Notes have a 12-month maturity date with a balloon payment and provide for the issuance of 258,353 common stock warrants at an exercise price of $0.88 and a term of 5 years. The stock price for warrants issued during the three months ended March 31, 2023 was $0.16 and was determined based on a 409a valuation as, at the time, there was still some uncertainty about the Business Combination. As discussed in Note 3, during the three months ended June 30, 2023, the probability of the Business Combination was determined to be 100%, and the stock price for those warrants was $0.62. It was based on the conversion ratio of Carmell shares into Alpha shares in connection with the Business Combination and the market price of the shares of Alpha, the acquiring public company.
The warrants became fully vested on the issuance date. As discussed in Note 2, the Company entered into a definitive agreement to merge with Alpha (the post-merger entity “New Carmell”). On the maturity dates, the Company will pay to note holders the principal in cash or, at the option of the Company, in shares of common stock of New Carmell at the average of the 10-day volume weighted average price if, in the reasonable judgment of the Board of Directors of the Company, at the time of such election, New Carmell Common Stock is listed on a stock exchange or is otherwise freely tradeable.
Proceeds from the sales of the Convertible Notes with stock purchase warrants were allocated to the two elements based on the relative fair value of the notes without the warrants and of the warrants themselves at time of issuance. The total amounts allocated to warrants were $55,062 and accounted for as paid-in capital. The discount amount was calculated by determining the aggregate fair value of the warrants using the Black-Scholes Option Pricing Model. As of June 30, 2023, there was $46,762 of unamortized debt discount. During the six months ended June 30, 2023, there was $8,300 of amortization of debt discount.
Advance from Related Party
The Company received a non-interest bearing advance of $25,000 from a member of the Board of Directors, which is outstanding as of June 30, 2023. Subsequent to June 30, 2023, the advance was converted to a promissory note with the same terms noted above in 2023 Promissory Notes.
NOTE 8 — COMMITMENTS AND CONTINGENCIES
On January 30, 2008, the Company and Carnegie Mellon University (“CMU”) entered into a License Agreement, as amended by that certain Amendment No. 1 to the Amended Exclusive License Agreement, dated as of July 19, 2011, as further amended by that certain Amendment No. 2 to the Amended Exclusive License Agreement, dated as of February 8, 2016, as further amended by that certain Amendment No. 3 to the Amended Exclusive License Agreement, dated as of February 27, 2020 and as further amended by that certain Amendment No. 4 to the Amended Exclusive License Agreement, dated November 23, 2021 (collectively, the “Amended Exclusive License Agreement”). This License Agreement provides the Company an exclusive, worldwide right to use certain technology of CMU relating to biocompatible plasma-based plastics to make, have made, use, and otherwise dispose of licensed products and to create derivatives for the field of use. The Company is required to use its best efforts to effect the introduction of the licensed technology into the commercial market as soon as possible and meet certain milestones as stipulated within the agreement. CMU retains the right to use any derivative technology developed by the Company due to its use of this technology and retains the intellectual property rights to the licensed technology, including patents, copyrights, and trademarks.
This agreement is effective until January 30, 2028, or until the expiration of the last-to-expire patent relating to this technology, whichever comes later, unless otherwise terminated under another provision within the agreement. Failure to perform in accordance with the agreed-upon milestones is grounds for CMU to terminate the agreement prior to the expiration date. As a partial royalty for the license rights, the Company issued 66,913 shares of the Company’s common stock to CMU. In addition, in 2008, the Company issued a warrant in 2008 for common stock to be exercised upon the earlier of (a) the Company’s cumulative capital funding and/or receipt of cumulative revenues collectively equals the sum of $2,000,000 or (b) thirty (30) days prior to any change in control event that provides for the issuance of shares that, when added to the number of shares then held by CMU, results in an amount equal to 8.2% of the outstanding shares of the Company. In 2011, CMU exercised the warrant in full, and the Company issued 1,607,705 shares of Common Stock. Prior to a qualified initial public offering or a qualified sale, CMU has the right to subscribe for additional equity securities to maintain its then percentage of ownership in the Company.
F-15
Royalties payable by the Company to CMU are 2.07% of net sales, as defined in the License Agreement. No royalties are due or payable for three (3) years following the effective date or until the closing of a change in control event, whichever occurs sooner. The Company shall also pay CMU 25% of any sublicense fees received, due, and payable upon receipt of the sublicense fees by the Company. All payments due to CMU are due within sixty (60) days after the end of each fiscal quarter. All overdue payments bear interest at a rate equal to the Prime rate in effect at the date such amounts are due plus 4%. Royalties accrued and paid during the six months ended June 30, 2023 and 2022, were $0.
The Company is obligated to reimburse CMU for all patent expenses and fees incurred to date by CMU for the licensed technology at the earlier of (1) three years from the effective date; (2) the closing date of a change in control event; (3) for international patents, from the start of expenses for patenting outside of the United States of America. There were no reimbursed expenses and no owed related to reimbursable expenses for the six months ended June 30, 2023 and 2022, respectively.
NOTE 9 — PROFIT-SHARING PLAN
The Company has a 401(k) profit-sharing plan covering substantially all employees. The Company’s discretionary profit-sharing contributions are determined annually by the Board. No discretionary profit-sharing contributions were made to the plan during the six months ended June 30, 2023 and 2022.
NOTE 10 — MEZZANINE EQUITY AND STOCKHOLDERS’ DEFICIT
Authorized Capital
In September 2022, the Company filed the Fourth Amended and Restated Certificate of Incorporation (the “Restated Certificate”). Such Restated Certificate shall, among other things: (i) terminate the Series C Convertible Preferred Stock, par value $0.001 per share, (ii) create a new Series C-1 Convertible Preferred Stock, par value $0.001 per share, having the terms set forth in the Restated Certificate; and (iii) create a new Series C-2 Convertible Preferred Stock, par value $0.001 per share. As a result of the amendment, the total number of shares of stock which the Company had authority to issue was 240,000,000 shares of common stock with a par value of $0.001 per share, and 171,090,521 shares of Preferred Stock, with 19,968,051 designated as Series A Convertible Preferred Stock (“Series A Preferred Stock”), and 34,622,470 designated as Series B Convertible Preferred Stock (“Series B Preferred Stock”), and 41,000,000 designated as Series C-1 Convertible Preferred Stock (“Series C-1 Preferred Stock”), and 75,500,000 designated as Series C-2 Convertible Preferred Stock (“Series C-2 Preferred Stock”).
Common Stock
Each share of common stock is entitled to one vote at all meetings of stockholders provided that, except as otherwise required by law, holders of common stock shall not be entitled to vote on any amendment to the Certificate of Incorporation that relates solely to the terms of one or more outstanding series of preferred stock if the holders of such affected series are entitled, either separately or together with the holders of one or more other such series, to vote thereon pursuant to the Certificate of Incorporation.
Preferred Stock
Since the preferred stock may be redeemed at the option of the holder, but is not mandatorily redeemable, the redeemable preferred stock has been classified as mezzanine equity and initially recognized at fair value of the proceeds on the date of issuance less issuance costs.
Series A Preferred Stock, Series C-1 Preferred Stock, and Series C-2 Preferred Stock accrue cumulative dividends at a per annum rate of 7% calculated on the original issue price of $0.2203, $0.2130, and $0.1712 per share (the “Original Issue Price”), respectively. Such dividends accrue on each share of preferred stock commencing on the date of issuance. Accrued dividends are not to be paid, other than upon a liquidation event or a redemption of the preferred stock, unless so declared by the Board, in which case the dividends so declared and paid shall reduce the dividends accrued on the preferred stock. In addition, if the Company pays a dividend on its common stock, it must first pay accrued dividends on preferred stock and then pay a dividend equivalent to the dividend on its common stock.
F-16
As of June 30, 2023, the Company has accrued dividends of $3,406,658, $47,109, and $676,255 for Series A Preferred Stock, Series C-1 Preferred Stock, and Series C-2 Preferred Stock, respectively. As of December 31, 2022, the Company has accrued dividends of $3,254,803, $9,470, and $239,104 for Series A Preferred Stock, Series C-1 Preferred Stock, and Series C-2 Preferred Stock, respectively. The Company accrued dividends of $151,855, $37,639, and $437,151 for Series A Preferred Stock, Series C-1 Preferred Stock, and Series C-2 Preferred Stock during the six months ended June 30, 2023.
Each share of preferred stock is convertible into one share of common stock at any time, at the holder’s option, subject to adjustments for stock dividends, splits, combinations, certain issuances at prices below the issue price of preferred stock, and certain other events. Holders of preferred stock are entitled to cast the number of votes equal to the number of shares of common stock into which shares are convertible. The holders of Series A Preferred Shares, exclusively and as a separate class, are entitled to elect one director of the Company. The holders of common stock, exclusively and as a separate class, are entitled to elect one director of the Company who must be the then-sitting Chief Executive Officer of the Company, and one director shall be selected and nominated by the then-sitting directors of the Company.
In the event of any distributions in cash or other property prior to a Deemed Liquidation Event as defined in the Restated Certificate, 70% of the distributions shall be paid ratably to the holders of Series B Preferred Stock before any payment made to the holders of Series C-1 Preferred Stock, Series C-2 Preferred Stock, Series A Preferred Stock, and common stock.
In the event of the liquidation or dissolution of the Company, the holders of Series C-1 Preferred Stock and Series C-2 Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to the Company’s stockholders before any payment shall be made to the holders of Series A Preferred Stock, Series B Preferred Stock, and common stock at the Original Issue Price per share plus any accrued but unpaid cumulative dividends, as applicable. Additional proceeds shall then be distributed to holders of Series B Preferred Stock at the Original Issue Price per share and then to the holders of Series A Preferred Stock at the Original Issue Price per share, plus the accrued but unpaid cumulative dividends before any payment shall be made to the holders of common stock. Any additional proceeds thereafter shall be distributed on a pro-rata basis to holders of preferred and common stock.
2009 Stock Incentive Plan
The Company has authorized the issuance of 45,072,120 shares under its 2009 Stock Incentive Plan (the “Plan”). Under the Plan, the Board may grant incentive and nonqualified stock options to purchase shares of the Company’s common stock to employees and other recipients as determined by the Board. The exercise price per share for an option granted to employees owning stock representing more than 10% of the Company at the time of the grant cannot be less than 110% of the fair market value. Incentive and nonqualified stock options granted to all persons shall be granted at a price no less than 100% of the fair market value and any price determined by the Board. Options expire no more than ten years after the date of the grant. Incentive stock options to employees owning more than 10% of the Company expire no more than five years after the date of grant. The vesting of stock options is determined by the Board. Generally, the options vest over a four-year period at a rate of 25% one year following the date of grant, with the remaining shares vesting equally on a monthly basis over the subsequent thirty-six months. Stock options are valued based on a hybrid approach combining a valuation approach (based on initial public offerings transactions and a market approach - option pricing model) and an equity allocation method.
Warrant and Option Valuation
The Company computes the fair value of warrants and options granted using the Black-Scholes option pricing model. The expected term used for warrants and options issued to non-employees is the contractual life, and the expected term used for options issued to employees and directors is the estimated period that options granted are expected to be outstanding. The Company utilizes the “simplified” method to develop an estimate of the expected term of “plain vanilla” grants for stock options. The Company utilizes an expected volatility figure based on a review of the historical volatilities over a period equivalent to the expected life of the instrument valued by similarly positioned public companies within its industry. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued. The Company’s stock price is derived from a 409a valuation.
F-17
Warrants Outstanding
The following table presents information related to common stock warrants for the six months ended June 30, 2023:
| Number of Warrants |
Weighted Average Exercise Price |
Weighted Average Remaining Contractual Life in Years |
||||||||||
| Outstanding and exercisable, December 31, 2022 |
5,190,325 | $ | 0.13 | 3.32 | ||||||||
| Warrants issued |
258,353 | 0.88 | — | |||||||||
| Warrants exercised |
— | — | — | |||||||||
| Warrants expired/cancelled |
— | — | — | |||||||||
|
|
|
|
|
|
|
|||||||
| Outstanding and exercisable, June 30, 2023 |
5,448,678 | $ | 0.16 | 2.92 | ||||||||
|
|
|
|
|
|
|
|||||||
The intrinsic value of the common stock warrants as of June 30, 2023 was $2,543,155.
The following table presents information related to Series B preferred stock warrants for the year ended June 30, 2023:
| Number of Warrants |
Weighted Average Exercise Price |
Weighted Average Remaining Contractual Life in Years |
||||||||||
| Outstanding and exercisable, December 31, 2022 |
821,253 | $ | 0.22 | 4.16 | ||||||||
| Warrants issued |
— | — | — | |||||||||
| Warrants exercised |
— | — | — | |||||||||
| Warrants expired/cancelled |
— | — | — | |||||||||
|
|
|
|
|
|
|
|||||||
| Outstanding and exercisable, June 30, 2023 |
821,253 | $ | 0.22 | 3.67 | ||||||||
|
|
|
|
|
|
|
|||||||
The intrinsic value of the Series B warrants as of June 30, 2023 was $324,477.
The following table presents information related to Series C-1 preferred stock warrants for the six months ended June 30, 2023:
| Number of Warrants |
Weighted Average Exercise Price |
Weighted Average Remaining Contractual Life in Years |
||||||||||
| Outstanding and exercisable, December 31, 2022 |
2,936,933 | $ | 0.16 | 9.73 | ||||||||
| Warrants issued |
— | — | — | |||||||||
| Warrants exercised |
— | — | — | |||||||||
| Warrants expired/cancelled |
— | — | — | |||||||||
|
|
|
|
|
|
|
|||||||
| Outstanding and exercisable, June 30, 2023 |
2,936,933 | $ | 0.16 | 9.24 | ||||||||
|
|
|
|
|
|
|
|||||||
The intrinsic value of the Series C-1 warrants as of June 30, 2023 was $1,493,137.
F-18
Option Activity and Summary
A summary of the option activity during the six months ended June 30, 2023 is presented below:
| Number of Options |
Weighted Average Exercise Price |
Weighted Average Remaining Life in Years |
Aggregate Intrinsic Value |
|||||||||||||
| Outstanding, December 31, 2022 |
36,320,980 | $ | 0.13 | 8.07 | $ | 1,083,492 | ||||||||||
| Granted |
1,250,000 | 0.16 | ||||||||||||||
| Exercised |
(235,255 | ) | 0.11 | |||||||||||||
| Expired/Cancelled |
(200,000 | ) | 0.11 | |||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Outstanding, June 30, 2023 |
37,135,725 | $ | 0.13 | 7.68 | $ | 17,973,338 | ||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Vested/Exercisable, June 30, 2023 |
17,686,471 | $ | 0.13 | 6.81 | $ | 8,663,411 | ||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
The weighted average fair value of the options granted during the six months ended June 30, 2023 was $0.12 per share, based on a Black Scholes option pricing model using the following assumptions:
| Expected volatility |
76.3 | % | ||
| Expected term of option |
6 years | |||
| Range of risk-free interest rate |
3.55% -3.75 | % | ||
| Dividend yield |
— |
During the six months ended June 30, 2023 and 2002, the Company recorded stock-based compensation expense for options of $367,539 and $342,866, respectively. As of June 30, 2023, there was approximately $1.77 million of total unrecognized compensation expense related to unvested stock options, which will be recognized over the weighted average remaining vesting period of 2 years.
NOTE 11 – RELATED PARTIES
A member of the Board of Directors holds investments in the Company through various venture capital firms. Certain family members of the CEO invested in Series B Preferred Shares, Series C-1 Preferred Shares, and Convertible Notes. The Convertible notes were converted into Series C-2 Preferred Stock on September 23, 2022.
The following table summarizes the related party transactions/balances in the Company at June 30, 2023 and December 31, 2022:
| June 30, 2023 | December 31, 2022 | |||||||||||||||
| Dollars | Shares | Dollars | Shares | |||||||||||||
| Series A Preferred Stock and Dividends |
||||||||||||||||
| Board Member |
$ | 877,054 | 4,222,223 | $ | 877,054 | 4,222,223 | ||||||||||
| Dividends Earned |
710,125 | 678,694 | ||||||||||||||
|
|
|
|
|
|||||||||||||
| $ | 1,587,179 | $ | 1,555,748 | |||||||||||||
|
|
|
|
|
|||||||||||||
| Series B Preferred Stock |
||||||||||||||||
| Board Member |
$ | 887,049 | 5,094,537 | $ | 887,049 | 5,094,537 | ||||||||||
| Immediate Family 1 |
103,244 | 780,967 | 103,244 | 780,967 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| $ | 990,293 | 5,875,504 | $ | 990,293 | 5,875,504 | |||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Series C-1 Preferred Stock |
||||||||||||||||
| Immediate Family 1 |
$ | 50,000 | 234,742 | $ | 50,000 | 234,742 | ||||||||||
| Accrued Dividends |
1,745 | 10 | ||||||||||||||
|
|
|
|
|
|||||||||||||
| $ | 51,745 | $ | 50,010 | |||||||||||||
|
|
|
|
|
|||||||||||||
F-19
| Series C-2 Preferred Stock |
||||||||||||||||
| Board Member |
$ | 1,049,381 | 6,129,561 | $ | 1,049,381 | 6,129,561 | ||||||||||
| Immediate Family 1 |
64,981 | 379,560 | 64,981 | 379,560 | ||||||||||||
| Immediate Family 2 |
64,279 | 375,464 | 64,279 | 375,464 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| $ | 1,178,641 | 6,884,585 | $ | 1,178,641 | 6,884,585 | |||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Series C-2 Accrued Dividends |
||||||||||||||||
| Board Member |
$ | 56,350 | $ | 19,924 | ||||||||||||
| Immediate Family 1 |
3,849 | 1,234 | ||||||||||||||
| Immediate Family 2 |
3,452 | 1,220 | ||||||||||||||
|
|
|
|
|
|||||||||||||
| $ | 63,651 | $ | 22,378 | |||||||||||||
|
|
|
|
|
In 2020, the Company granted 148,854 options to Immediate Family Member 2 for a fair value of $12,925 for consulting services. For each of the six months ended June 30, 2023 and 2022, the Company incurred an expense of $1,601 for these stock options.
As discussed in Note 7, the Company received an advance from a member of the Board of Directors and received proceeds from the issuance of promissory notes to related parties.
NOTE 12 – SUBSEQUENT EVENTS
Axolotl Biologix Acquisition
On July 26, 2023, Alpha entered into an Agreement and Plan of Merger (the “AxBio Merger Agreement”), by and among Alpha, Aztec Merger Sub, Inc. and Axolotl Biologix, Inc. (“AxBio”), which provides for, among other things, the merger of AxBio with and into Aztec Merger Sub, Inc., with AxBio being the surviving corporation of the merger and a direct, wholly owned subsidiary of Alpha (the “AxBio Acquisition”). The AxBio Acquisition closed on August 9, 2023. Pursuant to the terms of the AxBio Merger Agreement, all of the issued and outstanding shares of AxBio (other than the Dissenting Shares (as defined in the AxBio Merger Agreement) and the shares held in treasury) were canceled in exchange for aggregate consideration of (i) up to approximately $8.0 million in cash (the “Closing Cash Consideration”), (ii) a number of shares of Alpha’s common stock equal to (1) $57.0 million divided by (2) the value weighted average price of the common stock (the “VWAP”) for the 30 consecutive trading days immediately preceding the closing of the AxBio Acquisition (such consideration the “Closing Share Consideration”), and (iii) up to $9.0 million in cash and up to $66.0 million in shares of common stock that are subject to a performance based earn-out, subject to customary adjustments at closing for cash, working capital, transaction expenses and indebtedness, and amounts held back by Alpha. The AxBio Merger Agreement contains representations, warranties, and indemnification provisions customary for transactions of this kind.
On August 9, 2023, the Company entered into that certain First Amendment to the AxBio Merger Agreement (the “Amendment”) which amended certain terms of the AxBio Merger Agreement. The Amendment changed the structure of the AxBio Acquisition to provide that, following the merger of AxBio with and into Aztec Merger Sub, Inc., with AxBio surviving, AxBio would merge with and into Axolotl Biologix, LLC, with Axolotl Biologix, LLC being the surviving corporation of the merger and a direct, wholly owned subsidiary of the Company, and waived the condition requiring AxBio to deliver its audited financial statements upon closing in exchange for the $8.0 million of Closing Cash Consideration otherwise payable upon closing pursuant to the AxBio Merger Agreement becoming payable and contingent upon receipt of such audited financial statements.
On August 9, 2023, the Company completed the AxBio Acquisition. In connection with the closing of the AxBio Acquisition, the Company issued 3,845,337 shares of its common stock and 4,243 shares of a newly designated series of Series A Convertible Voting Preferred Stock, $0.0001 par value per share (the “Preferred Stock”), in exchange for all the issued and outstanding shares of AxBio as part of the consideration paid in connection with the AxBio Acquisition. The Closing Share Consideration was calculated using a 30-day average of daily VWAP of $7.05 per share. In addition to the shares of common stock and the Preferred Stock, the consideration included the Closing Cash Consideration, payable upon delivery of AxBio’s audited financial statements, as well as the Future Consideration. The number of shares of common stock issued at the closing of the AxBio Acquisition is limited to 19.99% of the total number of shares of the Company’s common stock issued and outstanding immediately prior to the closing. Pursuant tothe Certificate of Designation of Preferences, Rights and Limitations of the Preferred Stock, which was filed by the Company with the Secretary of State of Delaware on the closing date of the AxBio Acquisition in accordance with Section 151(a) of the Delaware General Corporation Law, each share of Preferred Stock will automatically convert into 1,000 shares of common stock upon stockholder approval of the issuance of the shares of common stock issuable upon such conversion and shall cease to have any rights other than with respect to conversion.
Stock Option Grants
In July 2023, the company made grants of 267,698 options to certain employees for shares of its common stock pursuant to the Company’s long-term incentive plan. These stock options expire ten years from the grant date, have a weighted average exercise price of $3.00, and vest over 5 years.
F-20
Exhibit 99.2
MANAGEMENT’S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF CARMELL THERAPEUTICS CORP.
You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes included as exhibits or incorporated by reference into the Current Report on Form 8-K, as amended (the “Current Report”), to which this discussion and analysis is filed as an exhibit. Unless the context otherwise requires, when we use the terms “we,” “us,” and “our” in the following discussion and analysis, we are referring to Carmell Therapeutics Corporation prior to the completion of the business combination with Alpha Healthcare Acquisition Corp. III (ALPA).
Cautionary Statement Regarding Forward-Looking Statements
In addition to historical information, some of the information contained in this discussion and analysis or set or incorporated into the Current Report, including information with respect to our plans and strategy for our business, future financial performance, expense levels, and liquidity sources, includes forward-looking statements that involve risks and uncertainties. You should read information included or incorporated into the Current Report under captions titled “Forward-Looking Statements” and “Risk Factors” for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.
Overview
We are a regenerative medicine biotech company focused on leveraging our core platform technology, Plasma-based Bioactive Material (“PBM”), to stimulate tissue repair or growth after severe injury, disease or aging. The technology is a proprietary method of utilizing fresh frozen platelet-enriched plasma to manufacture multiple forms to be placed directly at the anatomical site in need of enhanced and accelerated healing with the ability to reside in the local tissue for weeks to months. The PBM technology is based on important patents licensed from Carnegie Mellon University (“CMU”) that claim the ability to plasticize allogeneic platelet-enriched plasma and crosslink proteins with genipin, a derivative of the gardenia plant, to provide a controlled degradation profile in vivo. The Company’s lead product candidate, Bone Healing Accelerant (“BHA”), a biologic, has been designated by the U.S. Food and Drug Administration (“FDA”) as a combination product containing the Company’s core technology of PBM plus ß Tri-Calcium Phosphate (“ß-TCP”), an already approved medical device.
Recent Developments
On July 14, 2023 (the “Closing Date”), we consummated a business combination pursuant to the terms of the Business Combination Agreement, dated as of January 4, 2023 (the “Business Combination Agreement”), by and among the Company Alpha Healthcare Acquisition Corp. III a Delaware corporation, and Candy Merger Sub, Inc., a Delaware corporation (“Merger Sub”). Pursuant to the Business Combination Agreement, on the Closing Date, (i) ALPA changed its name to “Carmell Therapeutics Corporation,” and the Company changed its name to “Carmell Regen Med Corporation,” and (ii) Merger Sub merged with and into the Company, with the Company as the surviving company in the Business Combination. After giving effect to the Business Combination, the Company became a wholly owned subsidiary of ALPA.
On July 26, 2023, we entered into an Agreement and Plan of Merger (the “AxBio Merger Agreement”), by and among us, Aztec Merger Sub, Inc. and Axolotl Biologix, Inc. (“AxBio”), which provides for, among other things, the merger of AxBio with and into Aztec Merger Sub, Inc., with AxBio being the surviving corporation of the merger and a direct, wholly owned subsidiary of the Company (the “AxBio Acquisition”). The AxBio Acquisition closed on August 9, 2023. Pursuant to the terms of the AxBio Merger Agreement, all of the issued and outstanding shares of AxBio (other than the Dissenting Shares (as defined in the AxBio Merger Agreement) and the shares held in treasury) were cancelled in exchange for aggregate consideration of (i) up to approximately $8.0 million in cash (the “Closing Cash Consideration”), (ii) a number of shares of our common stock equal to (1) $57.0 million divided by (2) the value weighted average price of our common stock (the “VWAP”) for the 30 consecutive trading days immediately preceding the closing of the AxBio Acquisition (such consideration, the “Closing Share Consideration”), and (iii) up to $9.0 million in cash and up to $66.0 million in shares of common stock that are subject to a performance based earn-out, subject to customary adjustments at closing for cash, working capital, transaction expenses and indebtedness, and amounts held back us.
On August 9, 2023, the Company entered into that certain First Amendment to the AxBio Merger Agreement (the “Amendment”) which amended certain terms of the AxBio Merger Agreement. The Amendment changed the structure of the AxBio Acquisition to provide that, following the merger of AxBio with and into Aztec Merger Sub, Inc., with AxBio surviving, AxBio would merge with and into Axolotl Biologix, LLC, with Axolotl Biologix, LLC being the surviving corporation of the merger and a direct, wholly owned subsidiary of the Company, and waived the condition requiring AxBio to deliver its audited financial statements upon closing in exchange for the $8.0 million of Closing Cash Consideration otherwise payable upon closing pursuant to the AxBio Merger Agreement becoming payable and contingent upon receipt of such audited financial statements.
On August 9, 2023, the Company completed the AxBio Acquisition. In connection with the closing of the AxBio Acquisition, the Company issued 3,845,337 shares of its common stock and 4,243 shares of a newly designated series of Series A Convertible Voting Preferred Stock, $0.0001 par value per share (the “Preferred Stock”), in exchange for all the issued and outstanding shares of AxBio as part of the consideration paid in connection with the AxBio Acquisition. The Closing Share Consideration was calculated using a 30-day average of daily VWAP of $7.05 per share. In addition to the shares of common stock and the Preferred Stock, the consideration included the Closing Cash Consideration, payable upon delivery of AxBio’s audited financial statements, as well as the Future Consideration. The number of shares of common stock issued at the closing of the AxBio Acquisition is limited to 19.99% of the total number of shares of the Company’s common stock issued and outstanding immediately prior to the closing. Pursuant to the Certificate of Designation of Preferences, Rights and Limitations of the Preferred Stock, which was filed by the Company with the Secretary of State of Delaware on the closing date of the AxBio Acquisition in accordance with Section 151(a) of the Delaware General Corporation Law, each share of Preferred Stock will automatically convert into 1,000 shares of common stock upon stockholder approval of the issuance of the shares of common stock issuable upon such conversion and shall cease to have any rights other than with respect to conversion.
On August 1, 2023, our board of directors approved and adopted an amendment to our existing amended and restated certificate of incorporation to change the name of the Company from “Carmell Therapeutics Corporation” to “Carmell Corporation.”
Impact of Macroeconomic Events
Economic uncertainty in various global markets caused by political instability and conflicts, such as the ongoing conflict in Ukraine, and economic challenges caused by public health events, including the COVID-19 pandemic, have led to market disruptions, including significant volatility in commodity prices, credit and capital market instability and supply chain interruptions, which have caused record inflation globally. Our business, financial condition, and results of operations could be materially and adversely affected by further negative impacts on the global economy and capital markets resulting from these global economic conditions, particularly if such conditions are prolonged or worsen. Although, to date, our business has not been materially impacted by these global economic and geopolitical conditions, it is impossible to predict the extent to which our operations may be impacted in the short and long term. The extent and duration of these market disruptions, whether as a result of the military conflict between Russia and Ukraine and the effects of the Russian sanctions, geopolitical tensions, record inflation, or otherwise, are impossible to predict. Any such disruptions may also magnify the impact of other risks described or incorporated by reference in the Current Report.
Results of Operations for the Six Months Ended June 30, 2023 and 2022
The following is a comparative discussion of our results of operations for the six months Ended June 30, 2023 and 2022:
| For the Six Months Ended June 30, |
||||||||||||||||
| 2023 | 2022 | Change | % Change | |||||||||||||
| Revenue |
$ | — | $ | — | $ | — | — | |||||||||
| Operating expenses: |
||||||||||||||||
| Research and development |
$ | 1,563,982 | $ | 983,667 | $ | 580,315 | 59 | % | ||||||||
| General and administrative |
1,147,898 | 837,030 | 310,868 | 37 | % | |||||||||||
| Depreciation and amortization of intangibles |
50,375 | 47,019 | 3,536 | 7 | % | |||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total operating expenses |
2,762,255 | 1,867,716 | 894,539 | 48 | % | |||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Loss from Operations |
(2,762,255 | ) | (1,867,716 | ) | (894,539 | ) | 48 | % | ||||||||
| Other (expenses) income, net |
(4,375,412 | ) | 1,998,904 | (6,374,316 | ) | (319 | )% | |||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net (loss) income before taxes |
$ | (7,137,667 | ) | $ | 131,188 | $ | (7,268,855 | ) | (5,541 | )% | ||||||
|
|
|
|
|
|
|
|
|
|||||||||
Operating Expenses
Total operating expenses were $2,762,255 and $1,867,716 for the six months ended June 30, 2023 and 2022, respectively. The increase between periods was driven by increases in research and development and general and administrative costs. Higher expenses in the 2023 period are a direct result of executing our strategic plan to commercialize our technology.
Research and developments expenses were $1,563,982 and $983,667 for the six months ended June 30, 2023 and 2022, respectively. This increase was principally due to an increase in laboratory costs of $163,136, salaries and benefits of $159,435, lab supplies of $142,518, and clinical trial costs of $92,009. The majority of the research and development expenses are related to our lead product candidate, BHA.
General and administrative expenses were $1,147,898 and $837,030 for the six months ended June 30, 2023 and 2022, respectively. This increase was primarily driven by costs associated with recruiting of $144,529, accounting of $78,060, legal fees of $51,592, and stock-based compensation of $24,676.
Depreciation and amortization of intangible assets expense remained relatively flat for the six months ended June 30, 2023 compared to the same period of 2022.
Other Income (Expenses), Net
Other income (expenses), net were $4,375,412 for the six months ended June 30, 2023 as compared to other income (net) of $1,998,904 for the comparable period of 2022. The increase between years was primarily due to a change in the fair value of derivative liabilities of $7,787,773, partially offset by a decrease in the amortization of debt discount of $1,429,521.
Liquidity, Capital Resources, and Going Concern
As of June 30, 2023, and December 31, 2022 we had cash of $15,920 and $128,149 and a working capital deficit of $13,356,134 and $6,689,745, respectively. The decrease in working capital was driven by increases in derivative liabilities, promissory notes, accounts payable, and accrued expenses. To date, our liquidity has been satisfied through proceeds from the issuance of debt and equity securities.
The accompanying unaudited financial statements have been prepared on the basis that the Company will continue as a going concern, which assumes the realization of assets and the satisfaction of liabilities in the ordinary course of business. As of June 30, 2023, we had no income from continuing operations. Until the AxBio Acquisition, we did not have a marketed product or service. This has been the case since the Company’s inception and forces the Company to rely on continuously raising capital to fund the Company’s operations. While the Company completed the Business Combination in July 2023 (see Note 12 – Subsequent Events, Business Combination with Alpha Healthcare), we expect to require additional funding in the future. Management will need to raise additional funds by issuing equity securities or obtaining debt financing. There can be no assurance that any required future funding can be successfully completed on a timely basis or terms acceptable to the Company. Based on these circumstances, management has determined that these conditions raise substantial doubt about the Company’s ability to continue as a going concern.
Accordingly, the accompanying unaudited financial statements have been prepared in conformity with U.S. GAAP, which contemplates the continuation of the Company as a going concern, the realization of assets, and the satisfaction of liabilities in the ordinary course of business. The unaudited financial statements do not include any adjustments that might result from the outcome of this uncertainty. The unaudited financial statements do not include any adjustments that may be necessary should we be unable to continue as a going concern.
Cash Flows
The following table summarizes our cash flows for the six months ended June 30, 2023, and 2022:
| For the Six Months Ended June 30, |
||||||||||||||||
| 2023 | 2022 | Change | % Change | |||||||||||||
| Net cash used in operating activities |
$ | (956,137 | ) | $ | (2,227,586 | ) | $ | 1,271,449 | 57 | % | ||||||
| Net cash used in investing activities |
(30,470 | ) | (3,579 | ) | (26,891 | ) | 751 | % | ||||||||
| Net cash provided by financing activities |
874,378 | 2,304,509 | (1,430,131 | ) | (62 | )% | ||||||||||
Operating Activities
Net cash used in operating activities for the six months ended June 30, 2023 decreased by $1,271,449 as compared to the six months ended June 30, 2022. The reduction in cash used in operating activities was primarily driven by increases in accounts payable, accrued expenses, and other liabilities, partially offset by a higher loss from operations.
Investing Activities
Net cash used in investing activities was $30,470 and $3,579 for the six months ended June 30, 2023 and 2022, respectively, and was related to the purchase of property and equipment in both periods.
Financing Activities
Net cash provided by financing activities decreased by $1,430,131, primarily due to proceeds from convertible notes payable of $2,687,514 during the first six months of 2022, partially offset by the payment of debt financing fees of $382,222 and proceeds from the issuance of promissory notes of $823,500 in the first six months of 2023.
Off-Balance Sheet Arrangements
As of June 30, 2023, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K promulgated under the Exchange Act.
Contractual Obligations and Commitments
In addition to financing obligations under short-term promissory notes, convertible notes, and derivative liabilities, our contractual and commercial commitments include expenditures for clinical trials, leases, and royalty payments. For further information on our license agreement, see note 8 to our condensed financial statements.
Critical Accounting Policies and Estimates
This discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported expenses and net loss incurred during the reporting periods. Our estimates are based on our historical experience and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
There have been no material changes to our critical accounting policies and estimates during the six months ended June 30, 2023 from those described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” for the years ended December 31, 2022 and 2021, incorporated by reference into the Current Report.
Exhibit 99.3
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
Defined terms included below have the same meaning as terms defined and included elsewhere in the Current Report, unless defined below. As used in this unaudited pro forma condensed combined financial information, “Carmell” refers to Carmell Therapeutics Corporation prior to the Business Combination.
The unaudited pro forma condensed combined financial information has been prepared in accordance with Article 11 of Regulation S-X and presents the combination of the historical financial information of ALPA and Carmell, adjusted to give effect to the Business Combination and the other events contemplated by the Business Combination Agreement. Unless otherwise indicated or the context otherwise requires, references to the “Combined Company” refer to New Carmell and its consolidated subsidiaries after giving effect to the Business Combination.
The unaudited pro forma condensed combined balance sheet as of June 30, 2023, combines the historical balance sheet of ALPA as of June 30, 2023, and the historical balance sheet of Carmell as of June 30, 2023, on a pro forma basis as if the Business Combination and the other events contemplated by the Business Combination Agreement had been consummated on June 30, 2023. The unaudited pro forma condensed combined statement of operations for the six months ended June 30, 2023, combines the historical statements of operations of ALPA for the six months ended June 30, 2023, and the historical statements of operations of Carmell for the six months ended June 30, 2023 on a pro forma basis as if the Business Combination and the other events contemplated by the Business Combination Agreement had been consummated on January 1, 2022, the beginning of the earliest period presented. The unaudited pro forma condensed combined statement of operations for the year ended December 31, 2022, combines the historical statements of operations of ALPA for the year ended December 31, 2022, and the historical statements of operations of Carmell for the year ended December 31, 2022 on a pro forma basis as if the Business Combination and the other events contemplated by the Business Combination Agreement had been consummated on January 1, 2022, the beginning of the earliest period presented.
The unaudited pro forma condensed combined financial information and accompanying notes have been derived from and should be read in conjunction with:
| • | the historical unaudited condensed consolidated financial statements of ALPA as of and for the three and six months ended June 30, 2023, and the related notes, which are included in ALPA’s Quarterly Report on Form 10-Q filed with the SEC on August 14, 2023 (the “ALPA 10-Q”) |
| • | the historical audited financial statements of ALPA as of and for the year ended December 31, 2022, and the related notes, which are included in ALPA’s Annual Report on Form 10-K/A filed with the SEC on May 16, 2023 (the “ALPA 10-K/A”). |
| • | the historical unaudited condensed financial statements of Carmell as of and for the six months ended June 30, 2023, and the related notes; |
| • | the historical audited financial statements of Carmell as of and for the year ended December 31, 2022, and the related notes; and |
| • | other information relating to ALPA and Carmell contained in this Current Report, including the Business Combination Agreement and the description of certain terms thereof. |
The unaudited pro forma condensed combined financial information should also be read together with the sections of the ALPA 10-K/A and the ALPA 10-Q entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and the section of this Current Report entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” as well as other financial information included elsewhere in this Current Report.
Description of the Business Combination
On July 14, 2023 (“Closing Date”), ALPA, Merger Sub and Carmell consummated the Business Combination pursuant to which Merger Sub merged with and into Carmell, with Carmell surviving the Business Combination. Carmell became a wholly owned subsidiary of ALPA and ALPA was renamed “Carmell Therapeutics Corporation”. Each outstanding share of ALPA Class A Common Stock and each share of ALPA Class B Common Stock was converted into one share of Common Stock. Upon the consummation of the Business Combination, the consideration for the Business Combination was distributed as follows (in each case, rounded down to the nearest whole share):
| • | each outstanding share of Carmell common stock was cancelled and converted into the right to receive a number of shares of Common Stock equal to the Exchange Ratio (as defined in the Proxy Statement/Prospectus) of 0.06154; |
| • | each outstanding share of Carmell preferred stock was converted into Carmell common stock immediately prior to the Business Combination based on the applicable conversion ratio immediately prior to the Effective Time. The shares of Carmell common stock received upon such conversion were then cancelled and converted into the right to receive a number of shares of Common Stock equal to the Exchange Ratio of 0.06154; and |
| • | each outstanding option or warrant to purchase Carmell preferred or common stock was converted into an option or warrant, as applicable, to purchase a number of shares of Common Stock equal to (A) the number of shares of Carmell preferred or common stock subject to such option or warrant, on as converted basis, multiplied by (B) the Exchange Ratio at an exercise price per share equal to the current exercise price per share for such option or warrant divided by an Exchange Ratio between 0.06684 and 0.10070. The options and warrants to purchase shares of Common Stock are otherwise subject to the same terms. |
Other Related Transactions in Connection with the Business Combination
On July 9, 2023, ALPA and each of Meteora Special Opportunity Fund I, LP (“MSOF”), Meteora Capital Partners, LP (“MCP”) and Meteora Select Trading Opportunities Master, LP (“MSTO”) (with MCP, MSOF, and MSTO collectively as “Seller” or “Meteora”) entered into a forward purchase agreement (the “Forward Purchase Agreement”) for an OTC Equity Prepaid Forward Transaction. The primary purpose of entering into the Forward Purchase Agreement is to help ensure the Business Combination will be consummated. For purposes of the Forward Purchase Agreement, ALPA and the Combined Company are referred to as the “Counterparty” prior to and after the Business Combination, respectively.
Pursuant to the terms of the Forward Purchase Agreement, at the closing of the Business Combination, the Sellers purchased directly from the redeeming stockholders of ALPA 1,705,959 shares of the common stock of ALPA (“Recycled Shares”) at $10.279 which is the price equal to the redemption price at which holders of ALPA Common Stock were permitted to redeem their shares in connection with the Business Combination pursuant to Section 9.2(a) of ALPA’s Second Amended and Restated Certificate of Incorporation (the “Charter”) (such price, the “Initial Price”).
In accordance with the terms of the Forward Purchase Agreement, the Sellers were paid directly an aggregate cash amount (the “Prepayment Amount”) equal to (x) the product of (i) the Recycled Shares and (ii) the Initial Price, or $17,535,632.
The settlement date will be the earliest to occur of (a) the first anniversary of the Closing Date, (b) after the occurrence of (x) a Delisting Event or (y) a Registration Failure, upon the date specified by Seller in a written notice delivered to Counterparty at Seller’s discretion (which settlement date shall not be earlier than the date of such notice). The transaction will be settled via physical settlement. Any Shares not sold in accordance with the early termination provisions described below will incur a $0.50 per share termination fee payable by the Combined Company to the Seller at settlement.
From time to time and on any date following the Business Combination (any such date, an “OET Date”) and subject to the terms and conditions below, Seller may, in its absolute discretion, and so long as the daily volume-weighted average price (“VWAP Price”) of the Shares is equal to or exceeds the Reset Price, terminate the transaction in whole or in part by providing written notice (an “OET Notice”) in accordance with the terms of the Forward Purchase Agreement. The effect of an OET Notice given shall be to reduce the Number of Shares by the number of Terminated Shares specified in such OET Notice with effect as of the related OET Date. As of each OET Date, Counterparty shall be entitled to an amount from Seller, and the Seller shall pay to Counterparty an amount, equal to the product of (x) the number of Terminated Shares multiplied by (y) the Initial Price in respect of such OET Date (an “Early Termination Obligation”).
The Reset Price is initially $11.50 and subject to a $11.50 floor (the “Reset Price Floor”). The Reset Price shall be adjusted on the first scheduled trading day of every week commencing with the first week following the seventh day after the closing of the Business Combination to be the lowest of (a) the then-current Reset Price, and (b) the VWAP Price of the shares of the Counterparty’s common stock of the prior week; provided that the Reset Price shall be no lower than the Reset Price Floor.
On July 9, 2023, in connection with the forward purchase agreement, the Seller entered into a Non-Redemption Agreement with Alpha pursuant to which the Seller agreed not to exercise redemption rights under the Charter with respect to an aggregate of 100,000 Shares.
Accounting for the Business Combination
Notwithstanding the legal form of the Business Combination pursuant to the Business Combination Agreement, the Business Combination is accounted for as a reverse recapitalization in accordance with GAAP. Under this method of accounting, ALPA is treated as the acquired company and Carmell is treated as the acquirer for financial reporting purposes. Accordingly, for accounting purposes, the financial statements of New Carmell represent a continuation of the financial statements of Carmell, with the Business Combination treated as the equivalent of Carmell issuing stock for the net assets of ALPA, accompanied by a recapitalization. The net assets of ALPA are stated at historical cost, with no goodwill or other intangible assets recorded. Operations prior to the Business Combination are those of Carmell. Carmell has been determined to be the accounting acquirer based on an evaluation of the following facts and circumstances:
| • | Carmell’s existing stockholders have a majority of the voting power in New Carmell; |
| • | the New Carmell Board consists of nine directors, seven of whom were designated by Carmell and two of whom are designated by ALPA; |
| • | Carmell’s existing senior management team comprises the senior management of the Combined Company; and |
| • | Carmell’s operations prior to the Business Combination comprise the ongoing operations of New Carmell. |
Basis of Pro Forma Presentation
The unaudited pro forma condensed combined financial information has been prepared in accordance with Article 11 of Regulation S-X. The adjustments in the unaudited pro forma condensed combined financial information have been identified and presented to provide relevant information necessary for an illustrative understanding of New Carmell upon consummation of the Business Combination and the other events contemplated by the Business Combination Agreement in accordance with GAAP.
Assumptions and estimates underlying the unaudited pro forma adjustments set forth in the unaudited pro forma condensed combined financial information are described in the accompanying notes. The unaudited pro forma condensed combined financial information has been presented for illustrative purposes only and is not necessarily indicative of the operating results and financial position that would have been achieved had the Business Combination occurred on the dates indicated, and does not reflect adjustments for any anticipated synergies, operating efficiencies,
tax savings or cost savings. Any cash proceeds remaining after the consummation of the Business Combination are expected to be used for general corporate purposes. Further, the unaudited pro forma condensed combined financial information does not purport to project the future operating results or financial position of New Carmell following the consummation of the Business Combination. The unaudited pro forma adjustments represent management’s estimates based on information available as of the date of these unaudited pro forma condensed combined financial information and are subject to change as additional information becomes available and analyses are performed. ALPA and Carmell have not had any historical relationship prior to the transactions discussed in this Current Report. Accordingly, no pro forma adjustments were required to eliminate activities between the companies.
The following summarizes the pro forma shares of New Carmell Common Stock issued and outstanding immediately after the Business Combination:
| Number of Shares |
% Ownership |
|||||||
| New Carmell shares held by ALPA stockholders |
3,321,762 | 17.3 | % | |||||
| Founder Shares (1) |
3,861,026 | 20.1 | % | |||||
| New Carmell shares issued in merger to Carmell stockholders |
12,053,517 | 62.6 | % | |||||
|
|
|
|
|
|||||
| Shares outstanding |
19,236,305 | 100.0 | % | |||||
|
|
|
|
|
|||||
| (1) | All of the Founder Shares converted into shares of Common Stock on the Closing Date. |
The pro forma table above excludes New Carmell shares reserved for the future issuance of Carmell’s vested options and warrants, and ALPA Public and Private Warrants.
The following table summarizes the total New Carmell shares issuable to Carmell stockholders in connection with the Business Combination.
| New Carmell shares issued in merger to Carmell stockholders |
12,053,517 | |||
| Additional New Carmell shares reserved for the future exercise of Carmell stock options |
2,285,456 | |||
| Additional New Carmell shares reserved for the future exercise of Carmell warrants |
660,859 | |||
|
|
|
|||
| Total New Carmell shares issuable to Carmell stockholders |
14,999,832 | |||
|
|
|
If the actual facts are different than these assumptions, then the amounts and shares outstanding in the unaudited pro forma condensed combined financial information will be different and those changes could be material.
UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET
AS OF JUNE 30, 2023
(in thousands)
| Transaction | ||||||||||||||||||||
| ALPA | Carmell | Accounting | Pro Forma | |||||||||||||||||
| (Historical) | (Historical) | Adjustments | Combined | |||||||||||||||||
| ASSETS |
||||||||||||||||||||
| Current assets: |
||||||||||||||||||||
| Cash |
$ | 10 | $ | 16 | $ | 11,829 | (1 | ) | $ | 7,432 | ||||||||||
| 1,644 | (2 | ) | ||||||||||||||||||
| (2,280 | ) | (4 | ) | |||||||||||||||||
| (3,787 | ) | (9 | ) | |||||||||||||||||
| Deferred offering costs |
— | 1,317 | (1,317 | ) | (4 | ) | — | |||||||||||||
| Prepaid expenses |
54 | 6 | — | 60 | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||||
| Total current assets |
64 | 1,339 | 6,089 | 7,492 | ||||||||||||||||
| Marketable securities held in trust account |
160,237 | — | (29,347 | ) | (1 | ) | — | |||||||||||||
| (130,890 | ) | (2 | ) | |||||||||||||||||
| Operating lease right-of-use assets, net |
— | 788 | — | 788 | ||||||||||||||||
| Intangible assets, net of accumulated |
— | 26 | — | 26 | ||||||||||||||||
| Property and equipment, net |
— | 237 | — | 237 | ||||||||||||||||
| Forward purchase agreement asset |
— | — | 16,822 | (1 | ) | 16,822 | ||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||||
| Total assets |
$ | 160,301 | $ | 2,390 | $ | (137,326 | ) | $ | 25,365.0 | |||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||||
| LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ (DEFICIT) EQUITY |
| |||||||||||||||||||
| Current liabilities: |
||||||||||||||||||||
| Accounts payable |
$ | — | $ | 3,661 | $ | — | $ | 3,661 | ||||||||||||
| Accrued expenses |
2,815 | 1,613 | — | 4,428 | ||||||||||||||||
| Due to related party |
172 | — | — | 172 | ||||||||||||||||
| Income taxes payable |
1,123 | — | — | 1,123 | ||||||||||||||||
| Accrued interest |
— | 1,009 | (1,009 | ) | (9 | ) | — | |||||||||||||
| Advance from related party |
— | 25 | 25 | |||||||||||||||||
| Promissory notes, net of debt discount |
— | 708 | — | 708 | ||||||||||||||||
| Promissory notes-related parties, net of debt discount |
— | 69 | 69 | |||||||||||||||||
| Convertible notes payable, current |
— | 2,778 | (2,778 | ) | (9 | ) | — | |||||||||||||
| Derivative liabilities |
— | 4,697 | (4,697 | ) | (9 | ) | — | |||||||||||||
| Lease liability, current |
— | 135 | — | 135 | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||||
| Total current liabilities |
4,110 | 14,695 | (8,484 | ) | 10,321 | |||||||||||||||
| Lease liability, net of current portion |
— | 759 | — | 759 | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||||
| Total liabilities |
4,110 | 15,454 | (8,484 | ) | 11,080 | |||||||||||||||
| Commitments and contingencies |
||||||||||||||||||||
| Class A common stock subject to possible redemption |
158,593 | — | (29,347 | ) | (1 | ) | — | |||||||||||||
| (129,246 | ) | (2 | ) | |||||||||||||||||
| Redeemable Convertible Preferred stock |
||||||||||||||||||||
| Series A Preferred stock |
— | 7,866 | (7,866 | ) | (3 | ) | — | |||||||||||||
| Series B Preferred stock |
— | 7,025 | (7,025 | ) | (3 | ) | — | |||||||||||||
| Series C-1 Preferred stock |
— | 810 | (810 | ) | (3 | ) | — | |||||||||||||
| Series C-2 Preferred stock |
— | 16,341 | (16,341 | ) | (3 | ) | — | |||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||||
| Total redeemable convertible preferred stock |
— | 32,042 | (32,042 | ) | — | |||||||||||||||
| Stockholders’ (deficit) equity |
||||||||||||||||||||
| Common stock |
— | — | 1 | (3 | ) | 2 | ||||||||||||||
| 1 | (6 | ) | ||||||||||||||||||
| Class B common stock |
1 | — | (1 | ) | (6 | ) | — | |||||||||||||
| Common stock |
— | 15 | (15 | ) | (7 | ) | — | |||||||||||||
| Additional paid-in-capital |
— | 5,026 | 29,347 | (1 | ) | 60,687 | ||||||||||||||
| 32,041 | (3 | ) | ||||||||||||||||||
| (1,347 | ) | (4 | ) | |||||||||||||||||
| 394 | (5 | ) | ||||||||||||||||||
| 15 | (7 | ) | ||||||||||||||||||
| (5,047 | ) | (8 | ) | |||||||||||||||||
| 258 | (9 | ) | ||||||||||||||||||
| Accumulated (deficit) equity |
(2,403 | ) | (50,147 | ) | (2,250 | ) | (4 | ) | (46,404 | ) | ||||||||||
| (394 | ) | (5 | ) | |||||||||||||||||
| 5,047 | (8 | ) | ||||||||||||||||||
| 4,439 | (9 | ) | ||||||||||||||||||
| (696 | ) | (1 | ) | |||||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||||
| Total stockholders’ (deficit) equity |
(2,402 | ) | (45,106 | ) | 61,793 | 14,285 | ||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||||
| Total liabilities, redeemable convertible preferred stock and stockholders’ (deficit) equity |
$ | 160,301 | $ | 2,390 | $ | (137,326 | ) | $ | 25,365 | |||||||||||
|
|
|
|
|
|
|
|
|
UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS
FOR THE SIX MONTHS ENDED JUNE 30, 2023
(in thousands, except share and per share data)
| ALPA (Historical) |
Carmell (Historical) |
Transaction Accounting Adjustments |
Pro Forma Combined |
|||||||||||||||||
| Operating expenses |
||||||||||||||||||||
| General and administrative |
1,917 | 1,148 | — | 3,065 | ||||||||||||||||
| Research and development |
— | 1,565 | — | 1,565 | ||||||||||||||||
| Depreciation and amortization |
— | 50 | — | 50 | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||||
| Total operating expenses |
1,917 | 2,763 | — | 4,680 | ||||||||||||||||
| Loss from operations |
(1,917 | ) | (2,763 | ) | — | (4,680 | ) | |||||||||||||
| Other income (expense) |
||||||||||||||||||||
| Dividend and interest income |
3,542 | — | (3,542 | ) | (1 | ) | — | |||||||||||||
| Other income |
— | 34 | — | 34 | ||||||||||||||||
| Change in fair value of derivative liabilities |
— | (3,870 | ) | 3,870 | (2 | ) | — | |||||||||||||
| Interest expense |
— | (531 | ) | 531 | (2 | ) | — | |||||||||||||
| Amortization of debt discount |
— | (8 | ) | 8 | (2 | ) | — | |||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||||
| Net income (loss) before income taxes |
1,625 | (7,138 | ) | 867 | (4,646 | ) | ||||||||||||||
| Income tax provision |
(731 | ) | — | — | (731 | ) | ||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||||
| Net income (loss) |
$ | 894 | $ | (7,138 | ) | $ | 867 | $ | (5,377 | ) | ||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||||
| Weighted average shares outstanding of Carmell common stock - basic and diluted |
18,307,002 | |||||||||||||||||||
| Basic and diluted net loss per share - Carmell common stock |
$ | (0.42 | ) | |||||||||||||||||
|
|
|
|||||||||||||||||||
| Weighted average shares outstanding of Class A common stock subject to possible redemption - basic and diluted |
15,444,103 | |||||||||||||||||||
| Basic and diluted net income per share - Class A common stock subject to possible redemption |
$ | 0.05 | ||||||||||||||||||
|
|
|
|||||||||||||||||||
| Weighted average shares outstanding of Class B common stock - basic and diluted |
3,861,026 | |||||||||||||||||||
| Basic and diluted net income per share - Class B common stock |
$ | 0.05 | ||||||||||||||||||
|
|
|
|||||||||||||||||||
| Weighted average shares outstanding of Class A common stock - basic and diluted |
463,882 | 19,236,305 | ||||||||||||||||||
| Basic and diluted net income per share - Class A common stock |
$ | 0.05 | $ | (0.28 | ) | |||||||||||||||
|
|
|
|
|
UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS
FOR THE YEAR ENDED DECEMBER 31, 2022
(in thousands, except share and per share data)
| ALPA (Historical) |
Carmell (Historical) |
Transaction Accounting Adjustments |
Pro Forma Combined |
|||||||||||||||
| Operating expenses |
||||||||||||||||||
| General and administrative |
1,651 | 3,218 | 394 | (3) | 5,263 | |||||||||||||
| Research and development |
— | 2,196 | — | 2,196 | ||||||||||||||
| Depreciation and amortization |
— | 94 | — | 94 | ||||||||||||||
| Transaction costs |
— | — | 2,250 | (2) | 2,250 | |||||||||||||
| — | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||
| Total operating expenses |
1,651 | 5,508 | 2,644 | 9,803 | ||||||||||||||
| Loss from operations |
(1,651 | ) | (5,508 | ) | (2,644 | ) | (9,803 | ) | ||||||||||
| Other income (expense) |
||||||||||||||||||
| Dividend and interest income |
2,247 | — | (2,247 | ) | (1) | — | ||||||||||||
| Other income |
— | 11 | — | 11 | ||||||||||||||
| Change in fair value of derivative liabilities |
— | 1,259 | (1,259 | ) | (4) | — | ||||||||||||
| Loss on debt extinguishment |
— | (1,065 | ) | — | (1,065 | ) | ||||||||||||
| Interest expense, related party |
— | (52 | ) | — | (52 | ) | ||||||||||||
| Interest expense, non-related party |
— | (1,652 | ) | 1,652 | (4) | — | ||||||||||||
| Amortization of debt discount |
— | (2,044 | ) | 2,044 | (4) | — | ||||||||||||
| Gain on the settlement of the Convertible Notes |
— | — | 4,439 | (4) | 4,439 | |||||||||||||
| Loss on Forward Purchase Agreement |
— | — | (696 | ) | (5) | (696 | ) | |||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||
| Net income (loss) before income taxes |
596 | (9,051 | ) | 1,289 | (7,166 | ) | ||||||||||||
| Income tax provision |
(391 | ) | — | — | (391 | ) | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||
| Net income (loss) |
$ | 205 | $ | (9,051 | ) | $ | 1,289 | $ | (7,557 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||||
| Weighted average shares outstanding of Carmell common stock - basic and diluted |
28,546,036 | |||||||||||||||
| Basic and diluted net loss per share - Carmell common stock |
$ | (0.34 | ) | |||||||||||||
|
|
|
|||||||||||||||
| Weighted average shares outstanding of Class A common stock subject to possible redemption - basic and diluted |
15,444,103 | |||||||||||||||
| Basic and diluted net loss per share - Class A common stock subject to possible redemption |
$ | 0.01 | ||||||||||||||
|
|
|
|||||||||||||||
| Weighted average shares outstanding of Class B common stock - basic and diluted |
3,861,026 | |||||||||||||||
| Basic and diluted net loss per share - Class B common stock |
$ | 0.01 | ||||||||||||||
|
|
|
|||||||||||||||
| Weighted average shares outstanding of Class A common stock - basic and diluted |
463,882 | 19,236,305 | ||||||||||||||
| Basic and diluted net loss per share - Class A common stock |
$ | 0.01 | $ | (0.39 | ) | |||||||||||
|
|
|
|
|
Notes to Unaudited Pro Forma Condensed Combined Financial Statements
1. Basis of Presentation
The Business Combination was accounted for as a reverse recapitalization in accordance with GAAP. Under this method of accounting, ALPA was treated as the “acquired” company for financial reporting purposes. Accordingly, for accounting purposes, the financial statements of New Carmell represent a continuation of the financial statements of Carmell, and the Business Combination was treated as the equivalent of Carmell issuing stock for the net assets of ALPA, accompanied by a recapitalization. The net assets of ALPA are stated at historical cost, with no goodwill or other intangible assets recorded. Operations prior to the Business Combination are those of Carmell.
The unaudited pro forma condensed combined balance sheet as of June 30, 2023 gives pro forma effect to the Business Combination and the other events contemplated by the Business Combination Agreement as if they had been consummated on June 30, 2023. The unaudited pro forma condensed combined statement of operations for the year ended December 31, 2022 and the six months ended June 30, 2023, gives pro forma effect to the Business Combination, the other events contemplated by the Business Combination Agreement and the related transaction as if they had been consummated on January 1, 2022.
The unaudited pro forma condensed combined financial information and accompanying notes have been derived from and should be read in conjunction with:
| • | the historical unaudited condensed consolidated financial statements of ALPA as of and for the three and six months ended June 30, 2023, and the related notes, which are included in ALPA’s Quarterly Report on Form 10-Q filed with the SEC on August 14, 2023 (the “ALPA 10-Q”) |
| • | the historical audited financial statements of ALPA as of and for the year ended December 31, 2022, and the related notes, which are included in ALPA’s Annual Report on Form 10-K/A filed with the SEC on May 16, 2023 (the “ALPA 10-K/A”). |
| • | the historical unaudited condensed financial statements of Carmell as of and for the ix months ended June 30, 2023, and the related notes; |
| • | the historical audited financial statements of Carmell as of and for the year ended December 31, 2022, and the related notes; and |
| • | other information relating to ALPA and Carmell contained in this Current Report, including the Business Combination Agreement and the description of certain terms thereof. |
The unaudited pro forma condensed combined financial information should also be read together with the sections of the ALPA 10-K/A and the ALPA 10-Q entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and the section of this Current Report entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” as well as other financial information included elsewhere in this Current Report.
Management has made significant estimates and assumptions in its determination of the pro forma adjustments. As the unaudited pro forma condensed combined financial information has been prepared based on these preliminary estimates, the final amounts recorded may differ materially from the information presented.
The pro forma adjustments reflecting the consummation of the Business Combination are based on information available as of the date of this Current Report and certain assumptions and methodologies that management believes are reasonable under the circumstances. The unaudited condensed pro forma adjustments, which are described in these notes, may be revised as additional information becomes available and is evaluated. Therefore, the actual adjustments may materially differ from the pro forma adjustments that appear in this Current Report. Management considers this basis of presentation to be reasonable under the circumstances.
One-time direct and incremental transaction costs anticipated to be incurred by Carmell prior to, or concurrent with, the Closing are reflected in the unaudited pro forma condensed combined balance sheet as a direct reduction to New Carmell’s additional paid-in capital and are assumed to be cash settled. Since the Business Combination is accounted for as a reverse merger and recapitalization of Carmell into ALPA, the costs incurred by ALPA to consummate the merger are expensed as incurred.
2. Transaction Accounting Adjustments to Unaudited Pro Forma Condensed Combined Financial Information
Transaction Accounting Adjustments to Unaudited Pro Forma Condensed Combined Balance Sheet
The transaction accounting adjustments included in the unaudited pro forma condensed combined balance sheet as of June 30, 2023 are as follows:
| (1) | Reflects the liquidation and reclassification of cash and marketable securities held in the Trust Account that becomes available for general use by New Carmell following the Business Combination, the transfer of ALPA’s Class A Common Stock remaining after the redemption at the Closing Date to permanent equity and the forward purchase agreement asset. The adjustments are based on the number of shares of Class A Common Stock remaining after the redemption at the Closing Date of 2,857,880, including 1,705,959 shares of Class A Common Stock s subject to the Forward Purchase Agreement, and the redemption price of approximately $10.27 per share as of June 30, 2023. Pursuant to the terms of the Forward Purchase Agreement, at the closing of the Business Combination, Meteora purchased 1,705,959 shares of the Class A common stock including from holders that previously elected to redeem their shares of ALPA Class A common stock during the redemption period (“Recycled Shares”). In addition, Meteora was paid directly an aggregate cash amount (the “Prepayment Amount”) of $17,518,253 equal to (x) the product of (i) the Recycled Shares of 1,705,959 and (ii) the redemption price at which holders of ALPA Common Stock were permitted to redeem their shares in connection with the Business Combination (which is $10.27 at June 30, 2023). |
The Forward Purchase agreement was accounted for at fair value as a financial instrument in the scope of ASC 480 and resulted in an asset at the Closing Date. The fair value of the Company’s position under the Forward Purchase Agreement was calculated using the Call/Put Option Pricing Model. The valuation was prepared assuming the closing date of June 30, 2023. The features in the forward purchase agreement incorporated into the model included the termination fee of $0.50 per share, the risk-free rate of 5.37% and the term of one year. The difference between the fair value of the forward purchase agreement asset of $16,821,561 and the prepayment amount of $17,518,253 was expensed at the merger date.
| (2) | Reflects the cash disbursement for the redemption of 12,586,223 shares of Class A Common Stock (corresponding to the number of Class A Common Stock shares redeemed at the Closing Date) at a redemption price of approximately $10.27 per share (as of June 30, 2023), totaling approximately $130.9 million, net of the funds reserved for the payment of income and franchise taxes of approximately $1.6 million. |
| (3) | Reflects the exchange of all Carmell preferred stock (Series A preferred, Series B preferred, and Series C preferred) into New Carmell common stock pursuant to the conversion rate for such shares of Carmell preferred stock effective immediately prior to the Closing. |
| (4) | Reflects the preliminary estimated payment of direct and incremental transaction costs incurred prior to or concurrent with the Business Combination of approximately $3.6 million (exclusive of the deferred underwriters’ discount discussed below) which are to be cash settled upon Closing in accordance with the Business Combination Agreement. Transaction costs include legal, accounting, financial advisory and other professional fees related to the Business Combination. Of the total cash transaction costs of approximately $3.6 million, approximately $1.3 million are to be incurred by Carmell and charged to additional paid-in capital and approximately $2.3 million are to be incurred by ALPA and charged to expenses through accumulated deficit. |
| (5) | Reflects the non-cash charge of $0.4 million representing the compensation expense attributable to shares of Class B common stock transferred by the Sponsor to each of the three independent director nominees as compensation for their service on the board of directors, which awards vest simultaneously with the closing of an initial Business Combination. |
| (6) | Reflects the conversion of ALPA’s Class B Common Stock to Common Stock. |
| (7) | Reflects the recapitalization of equity as a result of the exchange of Carmell common stock for Common Stock at the Exchange Ratio. |
| (8) | Reflects the elimination of ALPA’s accumulated deficit to additional paid-in capital, including approximately $2.3 million of transaction costs incurred in connection with the Business Combination (refer to adjustment 4 above) and approximately $0.4 million of compensation expense discussed in adjustment 5 above. |
| (9) | Reflects the settlement of the Convertible Notes of Carmell upon the closing of the Business Combination under the terms of the Convertible Notes. Upon the closing of the Business Combination, the Convertible Notes would be settled at approximately $3.8 million in cash and through the issuance of 25,000 shares of New Carmell common stock (with a fair value of $10.30 per share as of June 30, 2023) recorded in the additional paid-in capital. |
Transaction Accounting Adjustments to Unaudited Pro Forma Condensed Combined Statement of Operations
The transaction accounting adjustments included in the unaudited pro forma condensed combined statement of operations for the six months ended June 30, 2023 are as follows:
| (1) | Reflects an adjustment to eliminate interest income related to the Trust Account. |
| (2) | Represents the elimination of the change in fair value of derivative liabilities, amortization of debt discount and interest expense incurred in relation to the Convertible Notes, as they are assumed to have been settled upon the closing of the Business Combination as of January 1, 2022 for pro forma purposes. |
The transaction accounting adjustments included in the unaudited pro forma condensed combined statement of operations for the year ended December 31, 2022 are as follows:
| (1) | Reflects an adjustment to eliminate interest income related to the Trust Account. |
| (2) | Represents the transaction costs expected to be incurred by ALPA. Since the Business Combination is expected to be accounted for as a reverse merger and recapitalization of Carmell into ALPA, the costs incurred by ALPA to consummate the merger are expensed as incurred. This adjustment is non-recurring in nature and is not expected to have a continuing effect on future period statements of operations. |
| (3) | Represents the non-cash expense of approximately $0.4 million representing the compensation expense attributable to shares of Class B common stock transferred by the Sponsor to each of the three independent director nominees as compensation for their service on the board of directors, which awards vest simultaneously with the closing of an initial Business Combination, which is assumed to have occurred as of January 1, 2022. This adjustment is non-recurring in nature and is not expected to have a continuing effect on future period statements of operations. |
| (4) | Represents approximately $4.4 million gain on the settlement of the Convertible Notes upon the closing of the Business Combination, which is assumed to have occurred as of January 1, 2022, as well as the elimination of the change in fair value of derivative liabilities, amortization of debt discount, and interest expense related to the Convertible Notes. Refer to adjustment (9) on the unaudited pro forma condensed combined balance sheet as of June 30, 2023. This adjustment is non-recurring in nature and is not expected to have a continuing effect on future period statements of operations. |
| (5) | Reflects the loss on the Forward Purchase Agreement as of the merger date. Refer to adjustment (1) related to the June 30, 2023 pro forma balance sheet. |
3. Loss per Share
Represents the net loss per share calculated using the historical weighted average shares of ALPA common stock outstanding, and the issuance of additional shares in connection with the Business Combination and other related events, assuming the shares were outstanding since January 1, 2022. As the Business Combination and other related events are being reflected as if they had occurred at the beginning of the period presented, the calculation of weighted average shares outstanding for basic and diluted net loss per share assumes that the shares issuable in connection with the Business Combination have been outstanding for the entire period presented. No unexercised stock options and warrants were included in the earnings per share calculation as they would be anti-dilutive.
| Six Months Ended | ||||
| June 30, 2023 | ||||
| Pro Forma Combined | ||||
| Pro forma net loss |
$ | (5,377 | ) | |
| Weighted average shares outstanding-basic and diluted |
19,236,305 | |||
| Net loss per share-basic and diluted |
$ | (0.28 | ) | |
|
|
|
|||
| New Carmell shares |
3,321,762 | |||
| hares (1) |
3,861,026 | |||
| New Carmell shares issued in merger to Carmell |
12,053,517 | |||
|
|
|
|||
| Shares outstanding |
19,236,305 | |||
| Year Ended | ||||
| December 31, 2022 | ||||
| Pro Forma Combined | ||||
| Pro forma net loss |
$ | (7,557 | ) | |
| Weighted average shares outstanding-basic and diluted |
19,236,305 | |||
| Net loss per share-basic and diluted |
$ | (0.39 | ) | |
|
|
|
|||
| New Carmell shares |
3,321,762 | |||
| Founder Shares (1) |
3,861,026 | |||
| New Carmell shares issued in merger to Carmell |
12,053,517 | |||
|
|
|
|||
| Shares outstanding |
19,236,305 | |||
| (1) | All of the Founder Shares converted into shares of Common Stock on the Closing Date. |
The following outstanding shares of common stock equivalents are excluded from the computation of pro forma diluted net income per share for all the periods and scenarios presented because including them would have an anti-dilutive effect.
| ALPA Public Warrants |
3,861,026 | |||
| ALPA Private Warrants |
115,971 | |||
| Carmell Warrants |
660,859 | |||
| Carmell Stock Options |
2,285,456 | |||
|
|
|
|||
| Total |
6,923,311 | |||
|
|
|